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ABSTRACT 
The rapidly chang ing biomedical device industry and the associated pace of the 
advancement of technology requires that biomedical device compa nies release products 
into the marketplace as fast as possible to recoup the investment made into them as well 
as to cope with fierce competition. An extens ive literature review was perfonncd to 
discuss the challenging areas in the product and process development of biomedical 
devices. These included the integration of advanced technologies, the integration of 
biomedical devices with the hum an body, government regulations, biomedical product 
liability issues, socia l and ethical issues, as well as sterilizat ion method s. This research 
proposed that the use of computer simu lation , in particular, SLAM II, can help 
biomanufacturing compa nies incorporate planned flexibility and strateg ic planning in 
product and process development , whi le addressing the challenges in the field of 
biomanufacturing. 
Although a well-p lanned process development can ensure rapid time-to-market 
and a more solid proprietary position for biomanufacturers , no research was found that 
investigated the use of simulation as a project management tool to accelerate biomedical 
device product and process development and to estimate the risks involved in the 
decision-making process. Therefore, this thesis addressed two important objectives in 
biomedical device project planning: minimizing project completion time and the 
associated risks. 
This research was concerned with the development of a methodology for creating 
product and process development plans using simulation technology. The Biomedical 
XII 
Operations Project Planning (BOPP) methodology was developed to aid project planners 
in the creation of biomedical device product and process development simulation models. 
The genera l biomedical device product and process development simulation model 
consists of 14 steps, from the development of the model to the analysis of the results. 
Severa l combina tions of nodes and activit ies (subnetworks) within SLAM II were created 
to facilitate the use of simulation in the project planning of biomedical devices. This 
research also developed necessary data co llection and general biomedical device 
simu lation model templates, thereby providing proj ect planners with the option of either 
modifying the templates to suit the needs of different medical devices or developing new 
simulation models using the instructions in the BOPP methodology. 
Finally , a model of product and process development of an external insulin pump 




The field of biotechnology has come a long way since early antiquity when the 
Chinese used moldy soybean curds as an antibiotic to treat boils and when the Greeks 
practiced crop rotation to maximize soil fertility. Over the past few decades, new 
bioteclmological developments have been made in the areas of hea lthcare, agricultural, 
and chemical or energy industries that greatly enhanced our quality of life. 
The biotechnology industry is a strong economi·c force. Total revenues for 
biotechnology companies increased from $17.4 billion in 1998 to $18.6 billion in 1999 
(Ernst & Young LLP, 1999). Table 1 shows biotechnology industry statistics from 1993 
to 1999 on sales, revenues, research and development (R & D) expenses , number of 
companies , and number of employees. The total number of biotechnology product 
patents granted from 1985 to 1998 is shown in Figure I (Biotechnology, 1999). The 
upward growth in the number of patents that were granted further confirms the strength 
of the biotechnology industry. 
Table 1: Biotechnology Industry Statistics. 
Year 1993 1994 1995 1996 1997 1998 1999 
Sales* 5.9 7.0 7.7 9.3 10.8 13.0 13.4 
Revenues* 8. 1 l0.0 11.2 12.7 14.6 17.4 18.6 
R&D 
4.9 5.7 7.0 7.9 9.0 Expenses* 7.7 
9.9 
Number of 
123 1 1272 13 1 I 1308 1287 1274 1283 Comoanies 
Number of 






















1985 1986 1 987 1988 1989 1990 1991 1992 1993 1994 1 995 1996 1997 1998 
Vear 
Figure 1: Total Biotechnology Product Patents Granted Per Year . 
As the medical technology industry grows, it requires timely transfer of concepts 
from research and development to product manufacturing. For a biomedical device or 
phaimaceutical manufacturer to remain on the competitive edge, not only is it necessary 
to satisfy the stringent demands of the biotechnology mark ets, but also to develop 
processes that can acce lerate the time from research and deve lopment to manufacturing 
and actual marketing of the medical products. 
The medical device industry has become one of the strongest sectors in the U.S. 
economy. This industry manufactures a wide range of products, from medical 
disposables to highly sophist icated diagnostic systems. The tenn "biomedica l device" is 
used to define medical devices that are integrated into or interactive with human systems, 
such as pacemakers, implant able cardioverter defibrillators, and implantabl e insulin 
pumps. Biomanufacturing has been defined as "the design, development , 
implementation, and management of systems for the production of products that are 
integrated into or interactive with human systems" (Grant, 1999). 
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Biomanufacturing is a potentially important area for product and process 
development analysis as it typically invo lves products that are expensive and complex, 
use rapidly changing technology, and are difficult to manufacture on a large-scale. In 
such high-techno logy industries, technologica l innovation and speed-to-market are 
dominant factors for survival. However, there are many factors that make 
biomanufacturing different from other types of manufacturing such as the importance of 
biomedica l device integrat ion with the human body, government regu lations on 
biomedical devices, biomedical products liability, social and ethical issues, and 
sterilization processes. These unique characteristics of blomanufacturing make it even 
more challenging for product and process planning. 
A lot of focus has also been placed on simultaneous engineering methods and on 
product and process cycles in order to shorten development times for general products. 
The product and process development time is extreme ly critical in the manufacture of 
high technology biomedical products due to the many processes and regulations involved 
as well as the extreme competition in the biomedical industry. Therefore, it is essentia l 
that new methods be used in biomanufacturing to manage the development and 
manufacture of these devices. 
This thesis explored the use of simulation as a project planning tool to support 
biomedical device product and process deve lopment. The following chapter provides a 
literature review of biomanufacturing, the product development process , project 
management, and the use of simulation as a too l for project planning, schedu ling, and 
control. Chapter 3 reviews the problems faced in the biomedica l industry with regard to 
product and process development, with a focus on biomedical device manufacturing. 
Chapter 3 also provides the objectives and scope of this research. Chapter 4 discusses 
Biomedical Operations Project Planning (BOPP). The BOPP is a methodology that was 
developed to show the application of simulation to the project platming of biomedical 
devices. The chapter also discusses simu lation subnetworks that were created to facilitate 
the use of simulation for biomedical device project planning. To aid project planners, it 
also provides templates for data collection and a genera l biomedical device simulation 
network model that can be modified and used to fit the needs of unique biomedical 
devices. Chapter 5 provides an example application of the BOPP methodology in 
managing the process development and manufac turing of an insulin pump. Chapter 6 
provides the summary and conclusions of this research as well as recommendations for 




This chapter first provides a back ground on biomanufacturing in Section 2.1. 
Section 2.1.1 describes existing biomedical device manufacturing technologies. Section 
2.1.2 discusses the issues related to biomedical device integration with the human body . 
Section 2.1.3 provides infonnation on govern ment regulations on biomedical device s. 
Section 2.1.4 reviews biomedical product liability. Section 2.1.5 covers social and 
ethical issues related to the development and manufacturing of biomedical products. 
Section 2.1.6 discusses the importance of sterilization in biom edical devices. 
Section 2.2 reviews the product development proce ss. Section 2.3 explains 
project management on a broad scope. Section 2.3.1, 2.3.2, and 2.3.3 examin e the 
elements of project planning, scheduling, and control. Section 2.4 discusses the use of 
simu lation in genera l manufacturing. Section 2.4.1 provides details on the use of 
simu lation as a tool for project planning, scheduling, and control. Finally, Section 2.4.2 
provides examples of computer simulation languages in existence today, with a focus on 
SLAM II. 
2.1 Problem Background 
Some of the processes used to manufacture biomedical devices and drugs employ 
similar combinat ions of standard operating procedures used to manufacture other 
products. However, there are many issues related to biomanufacturing that distinguish it 
from the manufacture of other products. The field ofbiomanufacturing is unique in terms 
of biomedical device manufacturing technologies, biomedical device integration with the 
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human body , government regulations on biomedical device s, biom edical product liability, 
social and ethical issues, and sterilization (Grant, 1999). 
2.1.1 Biomedical Device Ma1111fact11ring Tecft110/ogies 
Management of technolo gies in new product deve lopment (NPD) processes is a 
concern of NPD compani es and researchers (Scott, 2000). Scott investigated the 
importance of 24 technology management issues that contribute to decreased 
effect iveness ofNPD projects for high technolo gy products. An initial set of technolo gy 
management problems was developed based on the literature and the author's 
experiences. Us ing the DELPHI Questionnaire Management Issues Methodology, three 
questionnaires were distributed to the participants requesting them to rank the importance 
of the problems and provid e additional problems that were not included. The top ranked 
34 of the original 59 issues were included in the second questionnaire and the top ranked 
24 issues out of these 34 issues were used in the third questiotmaire. Any additional 
issues provided in the first questionnaire were added to the second questionnaire and 
likewise for the third questi onnair e. 
The results of Scott's study showed that strategic planning for technology 
product s was the most important issue. This catego ry included problem s with strategic 
and long-range plannin g for technology-prod uct development, such as aligning high 
technology strategies with business strategies (or vice versa if the technolo gy strategy 
should be dominant), new produ ct introduction strategies, strategic decision-making 
processes, lack of understandin g of technology and its roles among corporate strategic 
planners, lack of coherent corporate level planni ng for high technology management, 
failure to identif y the critical success factors of a company's technolo gy activities, and 
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establishing the corporation's technology climate. Since biomedical device 
manufacturing is high-technology manufacturing, it is important for a company to fonn 
strategic plans to manage the techno logy of medical devices. 
Some of the technologies that have been integrated in biomedical device 
manufacturing include Computer-Aided Design and Computer-A ided Manufacture 
(CAD/CAM) techniques. For example, new horizons have been created in the prosthetic 
field. In CAD, a prosthetic product is geometrica lly modeled in three dimensions using a 
computer so that it can be viewed and exami ned from all directions. One of the 
advantages of using CAD is that it provides the designer ·the opportun ity to experiment 
with design changes to the model, see the results, and analyze the appropriateness of 
those changes. Such models can be utilized for many other applications, such as 
manufacturing analysis. In CAM, numerically controlled machining processes can also 
be used for cutting out prosthetic devices. With this method, geometrical data taken from 
the CAD model are combined with machining parameters to produce the appropriate 
machining or cutting tool paths. This information can then be analyzed by graphic 
simulation to verify the process (Bok et al., 1990). 
Gupta and Wilemon (1996) studied Research and Development directors involved 
in research and development management and new product development efforts. The 
directors worked in 120 technology-based manufacturing finns consisting of chemical, 
electrical, electronics, information processing, telecommunications, instrumentation and 
control, and semiconductor industries. By distributing questionnaires comprised of 
several structured questions as wel l as a limited number of open-ended questions , they 
discovered that most of the directors agreed that open, frequent, and ear ly commun ication 
with customers and stakeholder s in areas such as researc h and development, marketing, 
manufacturin g is the key to success ful new product development. The results also 
showed that a majorit y of the companies use CAD, simulation tools, and other softwa re 
to make their produ ct development more effic ient. 
Advanced technolo gies in micromachini ng, due to increase d interest in the 
development of micro e\ectrome chanical systems (MEMS) , can also create dilemma s in 
manufacturing. Microdev ices are usuall y meas ured in tem1s of micrometers and are 
usual ly invisible to the naked eye. The manufacturing of these devices can cause unique 
problems. For example, factors such as vibration and gravity, that affect the operation s 
of other manufactured products such as gear assemblies, do not affect microdeviees. 
Instead, microdev ices are affected by other prob lems such as stiction , that is, the 
tendency of these devices to stick to one another. Examples of microde vices that are 
currently undergo ing research at Ohio State University are silicon microcapsu les 
(Nighswonger, 1999). These microcapsules are about the size of pinheads. They are 
implanted just below a patient 's skin with the capabilit y of carry ing health y tran splant 
cells to replace the patient's malfunctioning cells and produce needed chemica ls for the 
body. Microinstruments are also being developed for endoscopic procedures. These 
microdevices present many manufa cturing challenges as product developers are working 
on adding more advanced endosco pic functions wh ile maintaining the same micro-
dimensions. 
2.1.2 Biomedical Device illtegratio11 with the Human Body 
Another issue important to product deve lopers and manufacturers of biomedical 
devices is the integration of biomedical devices with the human body. Medical devices 
are govern ed by the International Organi za tion for Standardi zat ion (ISO) standard I 0093-
1, which states that " in the selection of materials to be used in device manufacture, the 
first co nsidera tion shou ld be fitness for purpo se havi ng regard to the characte ristics and 
properties of the material , wh ich inc lude chemical , toxicolo gica l, ph ysica l, electr ica l, 
morpholo gica l, and mechanical properties. " Th e docu ment also stat es that "the follow ing 
should be considered for their releva nce to the overa ll biolo gical eva luation of the device: 
a) the material(s) of manufactur e; b) intended additi ves, proc ess co ntaminant s and 
residues ; c) Ieac habl e substa nces; d) degrada tion produ cts; e) other compone nts and their 
interactions in the final produ ct; and f) the prop erties and chara cteristics of the final 
product" (Alb ert & Wallin , 1998). 
Medical device desi gners currently have limit ed typ es of mater ials to deve lop 
their produ cts. Table 2 illu strates some of these materials (Kohn , 1996). Howeve r, new 
resea rch in biomat erials aimed at creating sc ientific breakthroughs in the understanding 
o f ce ll-materials interactions can lead to improvements in disease treatment. 
Table 2: Materials Commonl y Used in the Manufacture of Medical Implants and 
Devices. 
Tvoc of Material Soecific Examo les 
Biostable polymers and resins 
Polyurethanes, silicone rubber, Teflonw, Dacronw, nylon, 
potymethytmethacrytate (PMMA) 
Biodegradable polymers Poly(lactic acid), poly(glyco lic acid), polydioxa none 
Natural and semi-synthe tic products 
Treated porcine grafts, bovine pericardium, processed 
ce llulose, processed co llage n 
Metals 
3 16 and 3 16L stainless stee l, Vital iumw, titanium alloys, Co-
Cr-Mo allov 
Ceramics 
Aluminum oxides, calc ium alumi nates , titanium ox ides, 
pyrolytic carbon, Bio glass®, hydroxyapatite 
Composites 
Apatite co mpos ites, carbon coa ted metals, carbon reinforced 
polymers 
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Plastics are also commo nly used in medical devices. They may be c lass i fled into 
five groups as shown in Table 3 (Leuscl mer & Rimpler , 1990). Although plastic s are 
useful for med ical devices , they can a lso cause problems such as chemica l react ivity, 
leachability , migration, biodegradation and mechanical abrasion. Plastics have the 
tendency to react chemica lly with the surrou ndin g tissue and body fluid s. The leachin g 
of material or ingredients from the plastics may also cause loca l or syste mic toxicity. 
Due to its dependency of shape and its passiveness, the host may try to rid itself of the 
implant caus ing migration of the product. Whet her desired or und esired, degradation of 
plastics is also of concern as wel l as the metabolic alteration of the plastic by the 
surrounding tissue. Plastics also pose problems in tem1s of abrasion and systemic 
deposition of the particles (Leuschner & Rimpler , 1990) . Therefore, product developers 
and manufacturer s need to be aware of these problems when developing biomedical 
devices to be integrate d with the human body. 
Table 3: Plastic Medical Device Classification . 
Grouo Examo les 
Permanent Implants 
Vascular grafts, hip prostheses, other artificial organs, 
oacemakers 
Materials in contact with mucosa! surfaces or Artificial eyes, contact lenses, denture s, intrauterine 
with the coni unctiva e devices, catheters 
Materials in contact with skin Solints, braces, films, orotective clothes 
Collection and administrative devices 
Blood transfusion sets, disposable syringes, cannulas, 
catheters, tubinQ, dialvzinQ units 
Storage devices 
Containers, bags for blood, blood products, diagnostic 
agents 
2.1.3 Gover11me11t Reg ulation s 
The U.S. Food, Drug, and Cosmet ic Act requires that all devices for human use be 
classified by the Food and Dru g Admi nistration (FDA) into one of three regulatory 
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classes so that each device will be subjec t to controls that are appropriate for that type of 
device (FDA, 2000). Class I appli es to med ical devices under General Contro ls. This 
requires the reg istration of manufacturers, record-keepin g, labelin g, and Good 
Manufa cturin g Practi ce (GMP) . Class JI appli es to medica l devices under Performance 
Standards. Medical devices in this class not onl y need to satisfy the requir ements of 
Genera l Controls , but must also meet perfom1ance standards in terms of materia ls, 
construction , compo nents, and prop erties. Class I and Class II medical devices usuall y 
require the submi ssion of Premark et Not ification (PMN) befor e being marketed. Finally, 
Class HI applies to all medical devices that need Premarket Approval (PMA). These 
medical devices need to be pre-ap proved by the FDA for safety and effec tiveness. A 
majority of these medical devices are implanted and are life supportin g or sustaining 
dev ices. Many Class Ill devices present a potential unreaso nable risk of illness or injury. 
The focus of the current research is on biomedical devices with in Class I and Class II that 
require PMN. 
2.1.4 Biomedical Product Liability 
Along with the tremendous grow th of the biomedica l industry is the issue of 
product liabilit y litigation . There have been numerous cases where pharmaceut ical and 
medical device manufacturers have had to remove their products from the market or file 
for bankruptcy due to heavy litigation and punit ive damage fees. Some of the more 
notabl e examples are the expe riences of the A. H Robbins Company with the Dalkon 
Shield intrauterin e device, Merrell Dow with the drug Bendect in, and G. D. Sear le & Co. 
with the Copper-7 intrauterine device (Price , 1987). Due to the risk associated with Class 
Ill product s, it is almost imposs ible for medical device and drug manu facturers lo buy 
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product liability insurance. Most of\en, these companies have to pay very high premiums 
or have self- insurance. 
Most biomedical device manufa cturers realize that even if a company successfu lly 
defends itself aga inst a lawsuit, the negative publicity can be highly undesirable to the 
biomedical device industry. A good examp le was the experience of Vitek, Inc. regarding 
their manufacture of an implant designed to treat temporo-mandibular joint (TMJ) 
syndrome (Kohn, l 996). A small amount of DuPont Teflon was used in the manufacture 
of this implant. Vitek, Inc. was forced into bankruptcy af\er some of the TMJ implants 
failed due to the poor resistance of Teflon to cont inuous mechanic al sheer. DuPont then 
withdrew its materials such as Teflon, Dacron, and Delcrin from the medical market 
although these materials were among the safest and most biocompatible materials 
available al the time. The Health Industry Manufacturers Association (l 994) estimated 
that the withdrawa l of these materia ls caused the shortage of 85 different medical 
products , affected 30 different surgical procedures, and reduced the quality of care given 
to an estimated 7.4 million patient s. 
According to Price (1987), medical device and drug manufacturers can reduce 
their product liabilit y by implement ing successfu l product safe ty program s. To prevent 
defects in design, manufacturers should choose appropriate designs for their products, 
document the decision-making process thoroughly, review the safety of the design chosen 
before actual production begins , and monitor product performance af\er the sale. 1n order 
to prevent defects in manufacturing, Price ( 1987) sugges ted that manufacturers use 
appropriate raw materials and component parts, require suppli ers to assume respons ibility 
for their products , estab lish rigorous quality contro l procedures, use appropri ate methods 
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of packag ing and shippin g the product , provide suffici ent instructions for the final 
assembly or installation of the product, and retain manufacturing documents to assist in 
product liabilit y suits. 
2.1.5 Social mu l Ethica l Issues 
Biomedical manufacturers also have to concern themselves with social and ethical 
issues when developing their produ cts. For exampl e, the subj ect of human cloning has 
been discusse d for years and is still a much-debated issue. "Clon ing" refers lo the 
growing of a colony of genetically identical cells or organjsms in vitro or the production 
of identical copies from a sing le entity, such as ce lls or genes (Cloning, 1999). Cloning 
is important to modem biomedical research, as it may increase the understanding of 
genes as well as ass ist in new drug and diagnostics deve lopment. How ever, there are 
groups who believe that thi s technolo gy can diminish individuality and personal 
autonom y. ll is important for biom edical companies to be aware of thes e different views 
before, duri ng, and after the development of their products. 
2.1.6 Sterilization 
Medical device sterilization is treated as a special manufacturing process in the 
ISO 9000 series because , unlike other products , the results canno t be verifi ed by 
inspecting and testing the product after the procedure. Sterili zation processes must be 
consistently monitored, assessed, and validated before and during use. "Biobur den" is 
the term used describin g " the population of viab le microo rganism s on a produ ct and/or a 
package" (Satter & Sorde llini, 1999) . There are man y factors attributing to the bioburd en 
on the produ ct and the packa ging, such as the origin of raw materials and compon ents , 
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material handling and storage factors, and the manufacturing environment in which the 
finished products are assembled and packag ed. Therefore, a well-designed test va lidation 
should ensure that bioburden is removed from the manufactured product. The steri lity 
assurance level (SAL) is "the probability of a viable microorganism being prese nt on a 
product unit after sterilization" (Satter & Sordellin i, 1999). This probability can neve r be 
reduced to zero through sterilization. However, by design ing a valida tion program that 
pro vides a high degree of confidence for cons istent sterilizat ion, this probability can be 
significantly reduced. According to Satter and Sorde llini (I 999), microbio logica l 
perfonnance qualification (MPQ) shou ld be done us ing specified products and packaging 
configured similarly to that in which they will be routi nely sterilized. For examp le, if a 
biomedi cal device manufacturer has the intention of using multiple load configurations, 
the densest configuration should be obtained for the MPQ. A well-designed MPQ can 
provid e the required SAL through an economical proce ss. It can a lso prev ent 
reprocessing and delays in the release of the product , a factor important in the 
manufacturing of biomedical devices. 
2.2 The Product Development Process 
Abernathy and Utterback (1978) created a model of the product life cycl e of 
inno vat ion. Acco rding to this model, in the be ginnin g phases of an industry's life, the 
rate of product innovation will be greater than the rate of process innovation. After 
experimentin g with various versions of the product in the market, a main des ign will 
grad uall y be chosen. At this point in time, competitors will stri ve to manufacture sim ilar 
products at lower cost and emphasis will be placed on pro cess innovation . Ther efore, 
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following thi s product life cycle model, pro cess innovation is on ly of paramount 
importance later in the Ii fe of an industry. 
During the last two decades, tim e-to-market has mov ed from obscurity to a 
prominent topic among product develo pers and manufacturers. Cost and perfonnanc e are 
no longer the chief metrics in detenninin g product succ ess. First-to-market products 
have the advantage of commanding higher initial prices and then garnering dominant 
market share and custom er loya lty. N um ero us studies and articles (see Guveritz (I 983), 
Fitzgerald ( 1987), Gold ( 1987), King ( 1987) , Uttal (I 987), Rosenau ( 1988, I 990), 
Dumain e (1989), Davis (1989) , Gupta & Wilemon (1990), Smith (1990) , Cordero (1991), 
Emman uelides (1991), McDonou gh & Barczak (1991), Morbey (1991), Ros enthal & 
March (1991), Symo nds (1991), and Crawford (1992)) have depicted the necessity of 
speed in the success of a product manufactur er and hav e provid ed suggestions on how 
product development cycle times can be improved. 
Severa l technique s have been suggeste d to acce lera te new product development , 
including the use of quality function deplo yme nt or QFD (Hau ser & Clausing, 1988), 
modif ying leaders hip sty les (McDono ugh & Barczak, 1992), depending on external 
sources of tech no logy and increas ing rewards for internal researc h and deve lopment 
perfonnance (Go ld, 1987), and improvin g the communication between research and 
development and other departments such as manufa cturin g and marketing (Gupta et al., 
1986). Table 4 pro vides more generic new produ ct development acce leration appro aches 
(Langerak et al., 1999). 
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Table 4: Generic New Product Development (NPD) Acceleration Approaches. 
Impl ementation of supp ort sys tems and Speedin g up activiti es/tasks: 
techniqu es : 
• CAD /CAM systems 
• CPM and PERT 
TQM 
New information and communication 
strategies 
QFD 
• Design for Manufacturability 
Reduction of parts /compo nents in 
product: 
Development of products of modular 
des ign 
Use of existing components /parts in 
designing new products 
• When designing products , take next 
generat ion products into account 
• Reduction of components /parts in 
new products 
• Emphasis on incre mental 
improvements instead of radical 
innovation s 
Speed up carry ing out activities in NPD 
process 
Link up NPD activities 
Carry out NPD activities simultaneously 
Elimination of slack time 
Reduction of time between idea gene rat ion, 
screening, and development 
• Reduction of interdependencies between NPD 
activ1t1cs 
Emphasizi ng time schedules and deadline s 
Supp lier inv olvement : 
EPA/CIM/mass customization 
Supplier involveme nt in NPO process in early 
stages ofNP D pro cess 
• Increasing qua lity requiremen t suppliers 
• Contract ou t design, development, and 
production of com ponent s/parts 
Involve supp liers in the production startup 
Reduc ing the suppl y base 
Reductio n of delivery times 
• Implementation of JIT/KANBAN 
Mi llson, Raj and Wilemon ( 1992) pinpointed five method s that companies can 
use to accelerate time -to-marke t: simplify operations, elim inate delays, eliminate steps, 
speed up operations, and process steps in parallel. They suggested simplify ing opera tions 
by integra ting tasks into mean ingfu l groups and by simplifying documentation . 
Elim inating delay s include s reducing marketin g plan s and launch delay s as wel l as 
linking research and development goa ls to manufactur ing capabiliti es. Eliminating steps 
includes reducing formal market testing, minimizing mark eting depa rtment approval, 
minimizing the number of parts used in the manufactu re of the products , and redu cing the 
number of steps in the assemb ly process. To speed up operations, the use of idea-
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generati ng groups, imp lementation of CAD or CAM, and installat ion of on-line product 
testing were suggested. To obta in parallel processing steps, tools such as Program 
Evaluation and Review Techn ique (PERT) and Critica l Path Method (CPMJ for task 
scheduling were suggested . 
Verganti (1999) stressed the importance of plan ned flex ibility in product 
development projects. Planned flexibi lity is "the capability to bu ild flex ibi lity into the 
deve lopment process due to decisions taken ear ly in the project." Verganti ( 1999) 
presented 18 Italian and Swedish companies with 35 typical decisions that are usua lly 
faced in the product deve lopment process. These decisions were taken from categor ies 
such as the project plan, product concept, product and process specifications , product 
design choices, and process design choices. Each of the 35 decis ions was reviewed and 
four different approaches to decision-making were identified. The approaches were 
summarized as either detailed, selective, comprehensive, or postponer. Companies that 
utilize the detailed approach are highly anticipative and spend a lot of time and effort 
during the early phase of a project to reduce uncertainty about downstream constraints 
and opportunities. Companies that use the selective approach anticipate only general and 
selective decisions in the early phase, giving the downstream phases the maximum 
degree of freedom to take advantage of unexpected opportunities. Companies that utilize 
the comprehensive approach combine the detailed and selective approaches by expecting 
as many decisions as possible in the early phase of the project. Companies that are 
postponers are not anticipative about downstream opportunities at all. An analysis of the 
perfom1ance of all 18 companies showed that none of these approaches were best for a 
particular company. Therefore , Verganti concluded that it was not the choice of the 
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approach to manage the early phase of a project, but the capability to carry on a given 
approach that made process development successful. 
2.3 Project Management 
According to Lientz and Rea (1995), a project is comprised of milestones and 
tasks or activities. Tasks or activities are units of work that lead to a milestone, a defined 
and tangible end product or goal. Project management is the process of managing, 
allocating, and timing resources in order to achieve a given objective in an expedient 
manner (Badiru, 1996). Project management encompasses planning, organizing, 
scheduling, and control functions. Project planning is the platfom1 for the start, 
implementation, and tennination of a project. This phase determines the course of 
actions and responsibilities required to achieve the project's goals. Project organization 
involves the determination of ways to integrate the functions of the personnel working in 
projects. The tasks involved in this phase are typically done concurrently with project 
planning (Badiru, 1996). 
Project scheduling is time-dependent and project activities are arranged according 
to precedence, time, and resource constraints to accomplish the project's objectives. 
Schedules are made according to a standard procedure that detem1ines the characteristics 
of production operations. Finally , project control ensures that suitable actions are taken 
to correct deviations from expected perfonnances (Badiru, 1996). 
2.3.1 Project Pla1111btg 
Project planning involves the determination of guidelines such as the objectives, 
project structure, tasks, milestones, personnel , costs , equipment , perfonnance, and 
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problem resolu tions (Badiru, I 996). Badiru observed that there are three prominent 
levels of project planning: supra level planning, macrolevel planning, and microlevel 
planning. 
At the supralevel planning stage, issues are viewed in the larger context by 
looking at how the project fits the overa ll and long-rang e organizatio nal goals in tenns of 
risk expos ure, management support, concurrent projects, market share, co mpany culture, 
financial stabi lity, shareholder expectat ion, and the effec t on the diminishing compa ny 
resources. The macro level planning level addresses the boundary of the project and its 
operational interfaces which include goa l definition , boundary of project , personne l and 
resource availabi lity, policies of the project , communication interfaces, deadlines, budget 
requirements, goal interactions , and conflict reso lution strategies. The microlevel 
planning stage looks in detail at the operationa l plans at the task levels of the project. 
Issues such as scheduled time, training and tools requirement, task procedures, reporting 
requirements , and quality requirements are analyzed (Badiru, 1996). 
In the microlevel plannin g phase, emphasis is placed on the compreh~nsiveness of 
details. A Work Breakdown Structure (WBS) is usually created to divide a project into 
greater levels of detail and measurable and controllable activities that can be easily 
understood in the fonn of a hierarchy (Dreger, I 992). The major objec tives of WBS 
include defining the efforts made for the project, the project scope and limitations, as well 
as the tangible and mea surable deliverables of the project. The WBS also helps to reduce 
the tendency to get sidetracked while working on tasks to fulfill project goals, as well as 
to structure the work into sma ller, detai led units that make it eas ier to define scope and 
deliverables. The WBS is a hierarchical structure that is typically either an indented 
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listing for tex tual represe ntation or a tree diagram, for graphical representation. 
According to Dreger (1992) and Ruskin and Estes (1995), some project managers have 
the tendency to skip this pha se in order to save tim e. How eve r, the overa ll cos ts o f the 
project will be higher if the plannin g ph ase is improp er ly coordinated. 
Badiru (1996) also outlined the components for a project plan. They includ e a 
brief summary of the project plan, objectives, approaches used, poli cies and procedures, 
contractual requirements, project schedule, reso urce requirements, performance 
measures, contingency plans as well as tracking, reporting, and auditing. 
2.3.2 Project Sched11/i11g 
Project scheduling invo lves resource availability analysis of human resources, 
material and capital, schedulin g techniques such as Critical Path Method (CPM), 
Program Evaluat ion and Review Technique (PERT), and Gantt charts, as well as trackin g 
and reporting of the proje ct (Kerzner, 1995). In project schedu ling, a netwo rk is 
composed of events and activities. An event is the start ing or ending point for a grou p of 
activ ities whe reas an activity is the work required to proceed from one eve nt or point in 
time to another. An exampl e of a PERT network is shown in Figure 2. The circles, 
called nodes, represen t even ts, and the arrows, called branches, represe nt activities. In 
the circles are numbers representing events or milestones. The number over the arrow 
denotes the time needed to proceed from one event to another event. Under each arrow is 
an activ ity number referencing each activity. 
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Figure 2: An Example of a PERT Network . 
A sequence of activ ities from the start ing node to the end ing node is defined as a 
path (Pritsker et al., 1994). Events 1-2-4-5 rep resent the critical path of this project 
network because this path has no slack time . Slack time is the calcu lated di fferencc 
between the latest allowable tim e on which an eve nt can be expected to take place and the 
latest time at wh ich an even t can take place without extending the comp letion date of the 
project (Kerzner, 1995) . 
The nome nclatu re and princip les for PERT and CPM netwo rks are similar. 
According to Kerzner ( 1995), there are four major diff erenc es between PERT and CPM 
netwo rks. A PERT network incorporat es three time est imate s (opti mistic, most likely, 
and pessimistic) and deri ves an expected time from these estimates. A CPM netwo rk 
uses only one time estimate close to actual time, resulting in better estimate accuracy. A 
PERT network is highly dependent on probabilities , derived from a beta distribution for 
activity times and a nom1al distribution for expected activity times. Therefore, it 
provides for the calculat ion of "risk" in finishing a project. A CPM netwo rk, however, is 
based on one time esti mate and is deterministic in nature. A PERT network is nonnally 
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utilized for managin g research and dev e lopment projec ts where there is high variability in 
calcu lating time durations. A CPM network is utilized for construction projec ts that are 
resource dependent and based on accurate time es timates . A PERT netwo rk is also used 
where the percentage of project completion is hard lo determin e exce pt al comple ted 
milestones. PERT networks , therefore, provide a measure of statistical uncertainty w hen 
estimating the duration of activit ies in a project. A CPM netwo rk is used where the 
percentage of project completion is easi ly determined. 
Gido (1985) , Bergen (1986) , and Modeler and Phillips (1970) found the following 
advanta ges of using PERT and CPM networks for project plam1ing: provid es a master 
plan; forces the use r to think through the entire project ; takes uncertaintie s into account; 
allows simulation of alternativ es; provides method for reporting on progress ; points out 
areas that are behind schedule ; helps in plannin g resource requir ements and allocations; 
focuses attention on the critical path; promote s awarene ss of projec t integration; helps to 
determine where to appl y lime -cos t trade-offs; helps to provide overa ll cost control; 
provides the plannin g team with a team spirit; and helps to train new proj ect manag ers. 
Spera (1998) described a survey that showed a relatively high incidenc e of failure 
in meeting produ ct deve lopment schedule s for both top and average performin g device 
manufacturer s. As show n in Figure 3, the incidence rate is often in excess of 20 perce nt. 
The study followed the perfom1ance of 288 compa nies, 28 of which were in the medical 
device and diagnostic industr y. In this study, "top performers" were compani es in the top 
20 percent of the participant s based on profit s from new product s, product 
commercia lization rate, and succe ss in meeting product schedules. The sc hedule s lip for 
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companies with high-comp lexi ty projec ts was show n to be greater than for compan ies 
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Figur e 3: Incid ence of F ailur e in Me eting Product Development Sch edul es for Top 
and Aver age Performin g Device Manufactur ers . 
2.3.3 Proj ect Co11trol 
In the project control phase, it is essent ial that projec ts be meas ured to find the 
difference between the planned performance and actual performance, and corrected to 
reschedule or expedite the task performance to meet the proj ects object ives (Bad iru, 
1996) . These actions may also include rea 11ocatio n of reso urces or project term ination. 
2.4 Simul ation 
With adva nceme nts in computer hardware and software tech nology. simulation is 
currently one of the most powe rful modeli ng tools in the manufac turing area. The 
increasing popu larity of simulation can be attributed to the introd uction of compute r-
assisted simu lation environments wit h speedy grap hic facilities, the greater 
respo nsiveness requ ired from current manufacturing systems due to the dyna mics of the 
bus iness environ ment, the increasing need for model ing tools for systems with stochastic 
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behav ior and state-dependent decis ion mechani sms, fewer rule s to follow in simula tion , 
greater flexibilit y given to the mod eler by simu lation, and the ease of interpretation of 
simu lat ion result s by decision mak ers. 
Simulation models are useful tool s for defining a collection of items that are the 
object of study or interest. According to Pritske r and O'Rei lly (1999), simulation mode ls 
can be used at five leve ls: 
• as explanatory dev ices to define a sys tem or prob lem, 
• as analys is vehicles to detem1ine critical clements, compon ents, and 
issues, 
• as design assessors to synthesi ze and evaluate proposed solutions, 
• as predictors to forecast and aid in planning future developme nts, and 
• as part of a system to provide on-line monito ring, status projections 
and decision support. 
The scope, boundarie s, and contents of a simu lat ion model are dependent on particu lar 
prob lems the model is designed to solv e. According to Law and Kelton (199 1), 
simulation mode ls also allow the assessment of potentia l performance before a newly 
designed syste m is operable , the comparison of various operating schemes of a present 
system without altering the ongoing performance of the system, and time compression or 
expan sion of the sys tem 's operation. 
Pritsker et al. (! 994) propo sed the following iterative steps in the modeling and 
simulation proc ess: 
• formulate the problem, 
• specify the mod el, 
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• build the mod el, 
• simul ate the model, 
• use the model , and 
• support deci sion makin g. 
To build a stron g simulation model , it is essenti al to first fonnulat e the probl em by 
compr ehendin g the problem, identif ying the goals, spec ifying perfom1anc e mea sures, 
setting model obj ectives, and defining the sys tem to be mode led. Second , the model is 
specified by identif ying the assumption s, data requir ements, compon ents, and the 
interaction of tho se compon ents. Third , the model is built by drawin g out the simulation 
mode l, coll ecting required data , and by definin g the experimental control s. Th e mod el is 
then simul ated. In thi s stage, the mod el is run , verified, and validated. After runnin g the 
model an appropri ate number of tim es, the interpretation and presentation of the outputs 
is per formed. Finall y, the results are used to support dec ision-makin g (Prit sker et al. , 
1994). 
2.4.1 Simulatio11 as a Too/for Project Pla1111i11g, Scheduling and Control 
Activity plannin g, schedulin g, and control are fundam ental in the mana ging o f 
manufacturin g sys tems. Althou gh there are many advantages o f using PERT and CPM 
networks for proj ect plannin g, Wiest and Levy ( 1977) sugges ted that PERT network s 
have the probl em o f prov idin g ove roptimi stic results in many appli cations. Gido (1985 ) 
and Bergen (1986 ) also presented the follow ing disadvantages o f PERT and CPM 
netwo rks: 
• the methods w ill not make decisions, 
• analyz ing the networks can be expensive , 
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• may lend credence to poor data, 
• may g ive a false se nse of sec urity, 
• networks can cross organizational bound s, 
• do not disp lay work load s, 
• the leve l of de tail may becom e confus ing, and 
• major revisions are difficult to inco rporate into existing netwo rks . 
Pril sker el al. (1994) also stated that PERT netwo rks have the followin g 
constraints : 
• the number of activ ity co mpletions required to release a node is equal to the 
number o f branches ending at a node, 
• all branching is done on a detenninistic basis, 
• no cyc les (feedback) are allowed in the network, and 
• projects are always comp leted successfu lly, as the concept of failure is 
nonexistent. 
Although PERT and CPM networks provide good comm unication vehicles to 
describe large proj ects in network form, Pritsker el al. (I 994) suggested the use of 
simulat ion to counter these network const raints. PERT and CPM networks also have 
many limit ations in terms of add ress ing issues of uncertainty. Mongalo & Lee (1990) 
proposed that uncertainties imp osed by random var iables be counte red by using a 
simu lation technique ca lled the Monte Car lo Sampl ing Techniqu e (MCST). This 
technique invo lves the random se lec tion o f activity times from an appropriate frequency 
distribution. The critica l path and the time needed lo comp lete the project are detem1ined 
using these results. The degree of acc uracy of the MCST model is dependent on the 
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number of time s the procedure is repeat ed. The output summary of the MCST provides 
values for the mean and variance of the project duration, produces the criti calit y index, 
which is the probability of an activit y being on the critic al path , and the proj ect risk, 
which is the probability of the proj ect being delayed after it is suppo sed to be compl eted. 
Mongalo and Lee (1990) attempted to detem1ine the network characteri stics that 
make the use of simulation preferable to the use of a PERT network. Th e results of their 
study reveal ed that on many occasions, the project duration s produ ced by PERT and 
MCST were statistically different. The underestimations of project compl etion times 
provid ed by PERT were mainly due to parallelism , siz e, and their interaction. The 
varyin g proj ect completion time s giv en by PERT and MCST wer e found to be due to the 
type s of distribution s used. Normally-distributed activitie s provided the shorte st project 
duration estimates, whereas values taken from uniformly-distributed frequencies 
pro vided the largest project duration estimate s. The beta and triangular distributions 
yielded stati sticall y similar conclusions. Mongalo and Lee (1990) not ed that, in many 
cases, the PERT method conclud ed that the project would be completed as scheduled , 
while the MCST method projected that there were high risk s that the proj ect would not be 
compl eted on time . They also observed that the MCST method for estimating project 
duration time was time-consuming. 
Badiru ( 199 I a) developed a computer simulati on pro gram named ST AR C to aid 
in proj ect plannin g. ST AR C was develop ed to simulat e proj ec t network s and perform 
"what-if ' analysis of projects involving probabilistic activity times and resource 
constraint s. ST AR C is a menu-dri ven pro gram compil ed in the BAS IC pro grammin g 
language for IBM- compatibl e comput ers. in proj ect schedulin g, ST ARC mak es the 
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following assumptions: resource availability is in whole units; no partial assignments of 
resources; spliuin g of activities and activity preemption are not allowed; total resource 
units required must be availab le befo re an activity can start; and all predecessors must be 
finished before an activity can start. 
In his approach to simulation modeling , Badiru (199lb) first conducted PERT 
activity time modelin g. Second, the project network was simulated using ST ARC. 
Third, managerial decisions were made based on the simulation output. The last step in 
the process consisted of running a statistical ana lysis of the simul ation output using 
STATGRAPHICS software . The study concluded that simulation is an effective tool to 
enhance planning and control methods in project management, as the methods and what-
if analyses that are provided with the simu lation are very beneficial to project ana lysts 
who must take uncertainties in project schedu ling into consideration. 
The Graphical Evaluation and Review Technique (GERT) was developed to 
analyze networks with stochastic activities and decision nodes (Prit sker & Happ , I 966). 
GERT is an extension of PERT and CPM network s as PERT and CPM can be class ified 
as a specia l class of GERT networks. The Venture Evaluation and Review Teclmique 
(VERT-3) was designed as another network mode ling teclmiqu e and computerized 
analysis system to assist in decision-making processes. This technique takes into 
consideration the time, cost, and perfom1ance at each node and branch, and generates 
critical paths for time, money and perfomiance measures (Lee et al., I 982). These 
techniques provide the basis for simulation modeling networks such as SLAM II, Visual 
SLAM, and SIMAN that exist today . 
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2.4.2 Comp uter S imul ation Languages 
Compu ter simulation began with programming languages such as C (Crookes, 
\ 989), C++ (Joines et al., I 992), Pascal (Piclcl, 1989), Fortran , and Basic (Pidd , I 988). 
However, these languages requir e extensive knowledge of coding and the deve lopment of 
simulation models was very slow. Process-orie nted simulation languages such as SLAM 
II (Pritsker , 1986), SIMAN (Pegden et al., 1986), and SlMSCRIPT (Greene, 1997) have 
been succe ss ful in decreasin g the programming burden on the simu lation modeler. These 
languages provid e subroutines for time advanc ement, entity maintenance, and statistics 
col lection. 
When given a model descript ion, SLAM II is a language that convert s the 
description into a fonn that can be recognized by the computin g system (Pritsker & 
O'Rei lly, 1999). The user anal yzes the outputs and make s appropriate changes to the 
model to find the optimal solution to the defined problem. The function s in SLAM II are 
accessible through pull-down menus and dialog boxe s chosen from the SLAM II 
Executive Window. AweSim 3.0 is a software that provides graphical implementatio n of 
the SLAM 11 language as well as a simulation probl em-solvin g environment for Visual 




The main object ive of this thesis was to develop the Biomedical Operations 
Project Planning (BOPP) methodo logy and to explore the application of simulation (in 
particular, SLAM 11) as a tool for project planning in biomedical device product and 
process development. An extensive literature search was performed to identif y and detail 
the challenging areas in the manufacture of biom edical devices. These include 
biomed ical device manufa cturing techno logies, biomedical device integration with the 
human body, govern ment regulation s on biomedical devices, biomedical product liability, 
soc ial and ethical issues, and ster ilizat ion (Gra nt, I 999). The literature review also 
showed that strateg ic planning and pla,med flex ibility are essential to ensure the growth 
of a com pany. 
The purp ose of this research was to show that the use of computer simulation can 
help biomanufacturing companie s in incorporating plann ed flexibility and strategic 
planning in product and process developm ent, whi le address ing the challenges in the field 
of biomanufacturing. This objectiv e was sat isfied through the developme nt of the BOPP 
methodology. 
The primary objectives of project scheduling are to make a product in the least 
amount of time , with the least cos t and risk (Kerzner, 1995). ln the biomanufacturin g 
industry, we ll-planned proces s deve lopment can ensure rapid time-to-market, fast 
production ramp-up, increased customer acceptance of new products, and a more solid 
proprietary position for biomanufacturers (Pisano, I 997). Although much researc h has 
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been done depicting the nece ss ity o f reducing time-to- market, none have focused on the 
booming biomedical dev ice industry, where speed in product and process dev elopment is 
of paramount importance. Biomedical de vice tec hnology changes so quickly that these 
prod ucts need to be re lease d int o the marketpla ce as quickly as possibl e to recoup the 
investme nt made in them. 
It is a lso particularl y import ant for biomanufa cturer s to be able to es timat e the 
risks involved in the decis ion-m aking process due to the time constraints and high costs 
assoc iated w ith the biomedical device indu stry. In thi s appli cat ion, risk is meas ured as 
the probability that a proj ec t pl an will exceed the due dates .or fail. 
A lthoug h many sugges tions have been made on how to improv e product 
developme nt cycle times and how to increase speed in manufacturing, no resea rch has 
been done to inves tigate the use of sim ulation as a project management too l to acce lerate 
biomedica l device product and process development. Furthermore, no previous research 
was found that considered the many issues that mak e b~ anufacturin g unique in the 
manufacturing industry or concentrated on the risks invo lved in decision-making in 
biomanufacturing. 
Therefo re, this thes is satis fied two of the thr ee object ives of project planning by 
invest igat ing the features in SLAM II that make it pos sible and adva ntageous for this 
language to be used in detem1inin g project duration s and risks. Due to the difficult y in 
access ing cost information from biom edical device companies , this research did not 
atte mpt to include costs as a factor in project planning . Thi s resea rch also pro vided 
necessary data collection and general biomedi cal device simulation mode l templates, 
thereby providin g project plann ers w ith the optio n of eithe r deve loping simul ation 
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models using the BOPP methodolo gy or modifying the templa tes to suit the needs of 
unique biomedical devices. 
The BOPP methodology deve lop ed in this the sis address ed the following uniqu e 
requirements in the development and manufacture of biomedical products: product 
development and process deve lopment failure and reengineering of those activities; 
governmen t regu lations and the approval proce ss, along with its imp act on product and 
process development; and multiple subprocess failures with time variant probabilities. 
Fina lly, a model of the product and process deve lopm ent of an insulin pump is 
provided as an exampl e application of the BOPP metho dolo gy. The deve lopm ent of the 
BOPP methodo logy for product and process dev elopm ent in the biom edica l device 




This chapter presents BOPP, a methodology that was created during this research 
for using comp uter simula tion as a tool for project planning in biomedical device product 
and process development. An assumption was made during the development of this 
methodology that the project planner has intermediat e und erstan ding and knowledge of 
the SLAM II language and is familiar with the AweSim 3.0 software. Details regarding 
this language can be found elsewhere (Pritsker et al., I 994; Pritsker and O'Reilly, 1999; 
Prit sker, 1986). 
A summary of the BOPP methodology is provided in Figure 4 in the fonn of a 
0owchart. The first step of the BOPP methodolog y is to collect the necessary data to 
create the project plan model. The second step is to det ennine the Task Groups of the 
biomedical device product and process development. A Task Group is a set of tasks 
focusing on a certain area in the product or process development such as Research and 
Development, Manufacturing, or Regulatory. The third step is to detennine the Primary 
Tasks within each Task Group. Primary Tasks are the specific main tasks that mu st be 
perfom1ed within each Task Group. The fourth step is to detem1ine Seco ndar y Tasks. 
Secondary Tasks are tasks within Primary Tasks that represent more detail to facilitate 
project planning. The fifth step of the BOPP methodology is to est imat e all task 
durations. Each task is provided a triangular distribution of an est imated longest (MAX) , 
most frequent (MODE) , and shortest (M[N) time. 
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4.1 Collect Data 
4.2 Determine Task Groups 
4.3 Determine Primary Tasks 
4.4 Detem1ine Secondary Tasks 
4.5 Estimate Task Durations 
4.6 Determine Precedence Between Primary Tasks 
4 .7 Determine Precedence Between Secondary Tasks 
4.8 Identify Potential Repeat Task s 4.9 Develop Flowchart and Create 
Phantom Repeat Tasks 
4.10 Estimate Probabilities of Pote ntial Repeat Task s and 
Phantom Repeat Tasks 
4.11 Develop Simulation Network Model 
4.12 Develop Simulation Control Statements 
4.13 Run Simulation Model 
4.14 Analy-Le Simulation Results 
Figur e 4: Biomedical Op eration s Proj ect Plannin g (BOPP) Meth odology. 
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The sixth and sevent h steps are to dctcm1ine precedences betwe en Primary Tasks 
and Seco ndary Tasks. Next, potential Repeat Tasks are identifi ed, and a nowch art is 
developed concurrently with the creation of Phantom Repeat Tasks. Potentia l Repeat 
Tasks are tasks that may need to be repeated either due lo perfonnanc e failure , reject ion 
of the biomedical device by the FDA, or merely for the necess ity of obtain ing repeated 
data. Phantom Repeat Tasks do not have any durations assigned lo them and are 
primarily used within the simulation model to represent logical looping of activities back 
to differ ent Task Group s or Primar y Tasks in the mod el. For example , they can be used 
to loop back to an earlier time to repeat tasks in the sim u'Iation mod el in the even t of a 
failure in one area of the project. 
Next , probabilities of potential Repeat Tasks and Phantom Repeat Task s are 
estimated. After that, the simulation network model is deve loped using the diff erent 
subnetwo rks provided, or by using the genera l biom edica l device simu lation network 
mode l as a templat e and modi fying it to suit the need s of a certain biomedical device . 
The simul ation control statements are then developed and the simulation model is 
exec uted. Fina lly, the results are analyzed to detem1ine initial performanc e results such 
as the estimated project completio n time and the risks associated with it. Dependin g on 
the desired accuracy of the results , the number of simu lation runs w ithin the simul ation 
con trol statements may then be modi lied to obta in a diff eren t set of perfonnance results. 
Within the propo sed methodo logy, genera l templates (a dat a collection templa te 
and a genera l biom edica l device simulation model templat e) have been deve loped and 
provided for the project plann er lo faci litate the use of this methodology in the project 
plannin g process. The data co llect ion template is in table form, as shown in Tabl e 5. 
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This template requires infonnat ion such as Task Groups (Column 4.2), Primary Tasks 
(Co lumn 4.3), Secondary Tasks (Co lumn 4.4), estimated dura tions of tasks (Column 4.5), 
Primary Task Precedences (Column 4.6), and Secon dar y Task Precedences (Column 4. 7). 
The general biomedi cal device simulati on model template is developed using the data 
co llection template and is presented later, in Section 4.11.8. 
The following discussion provides detail s on each of the steps in the BOPP 
methodology. 
4.1 Collect Data 
The first step in proj ect plannin g for biomedical device product and process 
development is to collect the necessary data to create the project plan model. Ln order to 
do so, it is necessary to define the function of the biom edical device as well as to 
determine the components or parts of the biomedical device. In the developm ent of 
BOPP, it is assumed that the physical design of the biomedical device has been 
comp leted. Data collection can be achieved through two methods: extensive literature 
research on biomedical device manufacturing and consultation with experts in the 
biomanufacturing field. For example, in order to determine the components of a 
biomedical device, documents such as the Bill Of Materials (BOM) may be used. 
Althou gh most start- up manufacturing fim1s wi ll not have documents like these in place, 
it is possible to obtain BOM samples related to a parti cular biomedical device from an 
external consulting finn, or even from another manufacturing company. This 
infonnati on will be helpful in detennining the components of the biomedical device, the 
raw materials required to produce the biomedical device, and how it should be 
manufactured. 
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Table 5: General Biomedical Device Project Planning Task Groups and Precedences Summary. r 
Task Primary Ta sk Secondary Task Duration 
Primary Task Seco ndar y Ta sk 
Group (4.3) (4.4) (4 .5) 
Precedenc e Precedence 
(4.2) (4.6) (4 .7) 
Detennine Biomedical 
Device Compone nts N one (RD_ l ) TRJAG (X, Y,Z) 
(Co mpon ents ) 
Identify Raw Materials 
Research and Specify Raw 
(Raw ) 
Materials for Biomedi ca l Device TRI AG (X,Y,Z) Compone nts 
(RD 2) 
Test for Suitability of Raw 
Materials for Biomedical Device TRJA G (X,Y,Z) RD_2 
(RD_3 ) 
Determine Production 
None(RD_4) TRIA G (X,Y,Z) Ra w 
Assemb ly Process (Prod) 
Determine Sterilizatio n Method 
TRIAG (X,Y,Z) Prod 
(RD 5) 
RD Determine and Test Analyze Effects of Steriliza tion 
Sterilization Method (RD 6) 
TRIA G (X,Y,Z) RD_5 
(Sterili za tion) 
Analyze Part icula te Con taminants 
TRJAG (X,Y,Z) . RD_ 6 
(RD 7) 
Determine Biocompatibility Run Tests To Invest iga te 
TR IAG (X,Y,Z) Sterilization 
(Biocoinpatibility) Biocompatibilit y (RD 8) 
Perform Failure-Mode-Effect 
TRIAG (X,Y,Z) RD_ S 
Analysis (RD 9) 
Identify Storage Crite ria 
None (RD _ I 0) TRIAG (X , Y,Z) Sterilization 
(Stora12:e) 
Determine Packagin g 
Identify Packaging Material 
TRIAG (X,Y,Z) Sterilizat ion 
(RD II) 
Mate ria l 
Evaluate Packa ging Material (Pa ckaging) 
(RD 12) 
TRJAG (X, Y,Z) RD - II 
w 
00 
Table 5: General Biomedical Device Project Plannin g Task Groups and Pr ecedences Summary (Co nt. ). 
Task Primary Task Secondary Task Durntion 
Prim ary Task Seco ndar y T ask 
Gro up (4.3) (4.4) (4.5) 
Pr ecedence Pr ecede nce 
(4 .2) (4.6) (4.7) 
Construct Preliminary GMP 
Manufacturing Facility None (MFG_!) TRIAG (X .Y,Z) Prod 
(GMP) 
Identify and Qualify 
None (MFG_ 2) TRIAG (X ,Y,Z) GMP 
Alternate Vendors (Vendor~ 
Install New Equipment 
None (MFG_3) TRIAG (X,Y,Z) Vendor 
(Equipme nt) 
Establish Fonnal Producti on 
Biocompatibility , 
Process (MFG_ 4) 
TRJAG (X,Y,Z) Storage, Packaging , 
Eouinment 
Determine Batch Size and 
Frequency of Manufacturin g TRIAG (X,Y ,Z) MFG _4 
Establish Formal (MFG _5) 
Production Process 
Discuss with Research Team and 
MFG (ProdProce ss) Confirm Each Step of Production TRJAG (X ,Y,Z) MFG_5 
Process (MFG_ 6) 
Propose New Techniques and 
Equipment for Scale -up TRIAG (X.Y,Z) MFG _6 
Manufacn1ring (MFG_7) 
Manufacture Biomedical Device 
TRIAG (X.Y.Z) ProdProcess 
Components (MFG_ 8) 
Manufacture, Assemble, Assemble Biomedical Device TRIAG (X,Y,Z) MFG_ 8 
and Test Biomedical Device Components (MFG 9) 
Components Test Biomedical Device 
TRJAG (X,Y,Z) MFG _9 (Manufacture) Components (MFG I 0) 
Assemble Final Biomedical 
TRJ AG (X, Y,Z) MFG 
Device (MFG I I) - 10 
Table 5: General Biomedical Device Project Plannin g Task Groups and Precedences Summar y (Cont.) . 
Task 
Primary Task Secondary Task Duration 
Primar y Task Seco ndar y Task 
Gro up 
(4.3) (4.4) (4.5) 
Pr ecedence Pr ecedence 
(4.2) (4.6) (4.7) 
Test Final Biomedical Device 
TRIAG (X,Y,Z) MFG I I 
(MFG_l2) -
Validate Biomedical Devic e 
TRIA G (X,Y,Z) MFG 12 
MFG Processing Events (MFG 13) 
-
(Cont.) Ensure Environmental 
Controls Follow No ne (MFG _ l4 ) TRIAG (X,Y,Z) Manufa cture 
Regulations (Environment) 
Perfonn Clinical Testing 
None (MFG_l5) TRIAG (X ,Y,Z) IDE 
(C linical ) 
File for Investigational 
None (REG_!) TRJAG (X,Y ,Z) 
Approval from IRB Environment 
(IA) WAIT TRIAG (X ,Y,Z) 
Submit lnvest igational None (REG _ 2) 
TRIAG (X,Y,Z) 
REG Device Exemption to FDA IA 
(IDE) WAIT TRIAG (X ,Y,Z) 
Submit for Premarket 
None (REG_3) TRI AG (X,Y,Z) . 
Notification Clini cal 
(PMN) WAIT TRIAG (X,Y,Z) 
Prepare Biomedical Device None 
TRIAG (X ,Y,Z) PMN 
For Market (PREPMARKET) 
BIOM EDI CAL DEVICE READY FOR MARKET 
It is important to emphas ize that obtainin g detailed BOM infom1ation may be difficult 
due 10 proprietary inte rests. However, for the purp ose o f creating a projec t plan model 
for biomedical device product development and manufacturing, only information 
regarding the basic top-leve l components of the medical device is needed, and this 
information can usually be acquired with minimal difficulties. 
Bes ides defining the components o f the biomedi cal device, it is also important to 
gather information regardin g necess ary tasks for the produ ct deve lopme nt and 
manu facturing o f the biome dical device. Tasks are the most basic buildin g blocks of 
proj ect plannin g. They define the work to be done to meet the goals of a projec t. A 
majorit y o f the infom1ation needed to create the methodolo gy for genera l biomedical 
device product and process deve lopment was obtained from the work of DeSa in (1993) 
as well as through interviews and correspondence with experts on the subjec t of 
biomedical device process deve lopment and manufa cturin g (J. Livingston, personal 
communi cation, Jun e 19, 2000). 
These research and consultation activiti es should not only place emphasis on the 
actual manu facturin g of medical devices, but also on the FDA regulations on these 
devices, as well as Good Manufacturin g Practices (GMP) . The inform ation co llected in 
this step will be utilized to determin e the essen tial Task Groups as well as Primary and 
Seco ndary Tasks in manufacturing a biomedical dev ice . 
4.2 Determine Task Groups 
The second step is to determine the necess ary Task Grou ps for product 
deve lopment and manufacturin g o f the biomedica l dev ice. A Task Group is a set of tasks 
focused on a particular phase o f product or process development. Most often, there are 
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three main phases or Task Groups in biomedical device product and process 
development. They are Research and Development (RD), Manufacturing (MFG) , and 
Regulatory (REG). These Task Groups arc shown in Column 4.2 in Tabl e 5. 
The RD Task Group may also be referred to as the Product Development Task 
Group. Biomedical device research describes and c lassifi es substances or processes 
deemed useful for therapeutic or diagnostic application (DeSain, 1993). This objective is 
fulfilled by exploring research or design cho ices in order to obtain a rational e for the 
product design. Biomedical device product development extends the basic research ideas 
to build a prototyp e or design of the device. The MFG Task Group is related to the actual 
manufacturing of the biom edical devi ce , and is also known as the Proces s D eve lopment 
Task Group. The REG Task Group is related to regulatory issues in the manufacturin g of 
biomedic al devices. 
4.3 Determine Primary Tasks 
The next step in the project planning of biomedical device product developm ent 
and manufacturin g is to determine all the Primary Tasks within each Task Group. 
Primary Tasks are essential tasks to be complete d within each Task Group. Primar y 
Tasks within RD include assessing and choosing raw materials, determining 
manufacturing options, and evaluating the product performanc e or rel iability. According 
to DeSain (1993), it is also in the research and development stage of a medical device 
that the required raw materials, quality requirements, product sensitivities, assembly 
requirements and methods, and product evaluation methodology is detem1ined. 
The Primary Tasks within the MFG Task Group include the construction of a 
preliminary GMP manufacturing facility, qualification of vendors, installation of new 
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equipment, confirmation on the final production process, as w ell as the manufacturing, 
asse mbly, and tes ting of each co mponent of the biomedical device w hile ensuring safe 
environmental controls. 
The REG Task Group includ es Primary Tasks such as obtaining the approv al 
from an Institutiona l Review Board ([RB), submi ssion for fnves tigationa l Device 
Exemption (IDE) to the FDA , and submiss ion for Premark et Not ification (PMN) , also 
known as 51 OK, or subm ission for Premarket Appro va l (PM A) (FDA, 2000a). Appro val 
from the [RB is necess ary as this commi ttee must confirm that they wil l supervi se the 
testin g of the biom edical dev ice, will prov ide approved, informed consent forms to the 
patients, and will ensure that prop er records and repo rts are filed . After obtai nin g the 
approval from the JRB, the IDE is usually filed. Th e appro val of this app lication 
provides penniss ion for the manufa cturer to use the product w ithin the state co mmerce 
for invest igational purp oses only. It also allows the manufa cturer to perform clin ical 
tes ting without strict adherence to the Food, Drug and Cos metic (FD&C) Act. Th en, 
dependin g on the class ification of the medica l device, a PMN or PM A is filed. A PMN is 
a docum ent submitt ed to the FDA when a medica l dev ice is to be com mercially 
introduced, but does not require a PMA (FDA, 1998) . Th ese devices are typica lly Cla ss I 
dev ices, and some Class II and Class III devices that are already in the mark et and have 
been detennin ed to be safe and effective by the FDA. A device requirin g PMA appro val 
is one which: 
• was not on the mark et before May 28, 1976, and is not substantially equi valent to 
a device on the market before May 28, 1976, or to a dev ice first marketed on or 
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after that date , which has been classified into Class I (General Controls) or Class 
II (Special Contro ls), or 
is required by a regulation issued under 5 1 S(b) or the FD&C Act to have an 
approved premarket approval application (PMA) or a declared completed product 
develop ment protoco l (PDP), or 
was regulated by the Food and Drug Administration (FDA) as a new drug or an 
antib iotic drug before May 28, 1976, and therefore is governed by 520(1) of the 
FD&C Act (transitional devices) (FDA, 2000b). 
Unlike the PMN , a PMA application is dependent on sufficient valid scientific 
evidence that provides assurance that the device is sare and effective for its intended use 
or users (FDA, 200 1 ). Column 4.3 in Table 5 identifies common Primary Tasks for 
biomedical device product and process development. Each of the tasks is given a unique 
label so that it will be easily identifiable in the future. For example, the Primar y Task, 
"Detennine Biomedical Device Components" is given the label "Compo nents." 
4.4 Determine Secondary Tasks 
After specification of Primary Tasks, Secondary Tasks are detennined, ir any. 
Secondary Tasks are Primary tasks that are broken down so that they are easier to 
manage for project plannin g purposes. 
Column 4.4 in Table 5 identifies Secondary Tasks within the Primar y Tasks for 
biomedical device product and process development. Like Primary Tasks , the Secondary 
Tasks are also given unique labels for ease of future identification. All the Secondary 
Tasks within the RD Task Group are given labels that started with "RD", followed by an 
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underscore and a number. For example , the Secondary Task, "Research and Specify Raw 
Materials for Solenoid Motor" is given the label, "RD_2." Similarly, all the Secondary 
Tasks within the MFG Task Group are provided labels that start with "MFG", followed 
by an underscore and a number. All of the Secondary Tasks within the REG Task Group 
are provided labels that start with "REG", followed by an underscore and a number. If a 
Primary Task is not broken down into Secondary Tasks, a label with the same fonmat is 
also provided within this column. 
Tasks that fall under the "REG" category usually have WAIT times. WAIT time 
is used when an application for FDA approval is submitted and the company has to wait 
for a response before proceeding to the next task. Therefore, each task within this 
category is allowed WAIT time within the Secondary Task column. 
The final task is usually to "Prepare Biomedical Device for Market", and is 
labeled "PREPMARKE T." 
4.5 Estimate Duration of Tasks 
All durations of Secondary Tasks as well as Primary Tasks that are not comprised 
of any Secondary Tasks are then specified. The durations of Primary Tasks that are 
comprised of Secondary Tasks do not need to be specified because the sum of the 
durations of all Secondary Tasks within a Primary Task is the duration of that Primary 
Task. For simulation modeling purposes, the required data are estimates of the longest 
(MAX or "X"), most frequent (MODE or "Y") , and shortest (MIN or "Z") possible 
duration for each of these tasks. A triangular distribution that includes these durations 
was chosen because the project planner may not actually know the distribution of the 
project durations but should find it relativel y easy to provid e the longest, most frequent, 
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and shortest durations of the tasks. Hence, the triangular distribution will provide a good 
approximation. Estimated durations are obtained from sources such as historical data, 
estimates from personnel who will perform the required tasks, and expert opinions from 
project managers, professionals or industry organizations that have exper ience on similar 
projects (Chatfield & Johnson, 2000). Since these durations vary with different projects 
and are often manipulat ed, it is not possible to genera lize a duration for each task. 
Therefore, it is left up to the project planner to estimate the task durations for Column 4.5 
in Table 5. 
4.6 Determin e Precedences between Primary Tasks 
It is also necessary to determine precedences between Primary Tasks. 
Precedences occur when the ending event for a task must happen before starting another 
task. It is possible that severa l Primary Tasks must end before the start of another 
Primary Task. Column 4.6 in Tab le 5 shows precedences for the biomedical device 
product and process development Primary Tasks determined in Section 4.3. These 
Primary Task links were determined by linking and confirming infonnation in DeSain's 
handbook through correspondence with experts in biomedical device product and process 
development (J. Livingston, personal communication, June 19, 2000). 
4. 7 Determine Precedences between Secondary Tasks 
The precedences between Secondary Tasks are similarly determined, by taking 
into consideration that the ending event for more than one Seconda ry Task may occur 
before the start of another Secondary Task. Column 4.7 in Table 5 shows precedences 
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for the biomedical device product and process deve lopment Seco ndary Tasks determined 
in Section 4.4. 
4.8 Identify Potential Repeal Tasks 
Due to the strict regulations in biomedical dev ice manufacturin g, as wel l as the 
comp lexity of the biomedical device itself, there are many instances where the need 
arises for tasks to be repeated, either due to performanc e failure, rejection of the 
biomedical device by the FDA, or merely due to the necessi ty of obtaining repeated data. 
These tasks are ca lled Repeat Tasks. The identification of potentia l Repeat Tasks is 
performed while developing the flowchart in Section 4.9. One example of a potential 
Repeat Task is the Secondary Task, "Determ ine Sterilization Method (RD _5)." This 
task may be repeated if the tests performed in Secondary Tasks, "Ana lyze Effects of 
Ster ilization (RD_6)" or "Analyze Particulate Contaminants (RD_7)" fail to pass a 
chosen sterilization method. Likewise, after Secondary Task, "Eval uate Packaging 
Material (RD_ l2)" is performed, it is possible that the chosen packaging materia l is 
deemed unsuitabl e. Therefore, there is a poss ibility of repeating the Secondary Task, 
"Identify Packaging Materia l (RD_ 11 )" to recommend another type of packaging 
materia l to be tested. 
4.9 Develop Flowchart and Create Phantom Rep eat Tasks 
Using the infonnation gathered from Sections 4.1 to 4.8, a flowchart is developed 
to provide a pictorial flow of a general biomedical product and process development 
project. If the project planner chooses to use the information in Table 5, he or she can 
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also utilize this flowchart and if necessary, modify it accord ing to his or her unique 
needs. 
The flowchart in F igure 5 shows that the general biomedical device product and 
process development is compr ised of the three major Task Groups: RD, MFG, and REG. 
The RD phase invol ves the research and development of raw materials and their 
preparation for manufacturing. The MFG phase is the actual manufacturing of the 
biomedical device. The REG phase involves the handling of documents for the 
regulatory approval processes. 
In the BOPP methodology, it is assumed that · the RD phase begins after 
confinnation of a biomedical device design. First, the components of the biomedical 
device are determined (RD _ I). Once this has been don e, the raw materials for each of 
the components is researched and documented (RD _2). The raw materials are then all 
tested to detem1ine whether they are suitab le for the biomedical device (RD _3). Raw 
material tests include infrared or nuclear magnetic resonance, densi .ty, hardn ess, porosity, 
elasticity, radiopacity, morphology, gas or moisture permeation, wetting characteristics of 
surface, thermal properties, stress-strain relationships, physico-chemical tests of 
extractab les or leachab les, particulate contaminants and electro magn et ic radiation effects 
(DeSain, 1993). The cost of the planned raw materials is also taken into consideration. 
This process is iterated until suitable raw material for each component is found. Once the 
raw materials are confirmed, the production assembly process is determined (RD_ 4). 
The detem1ination of the production assembly process is done while placing the utmost 
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Figure 5: General Biomedical Device Product and Process Development Flowchart 
(Cont.). 
phase begins and flows concurrent ly with the RD phase in order to speed up design-to-
market time. The RD phase is continued with the determination of steril ization method 
options (RD_S). The effects of diff erent sterilization method s are then analy zed (RD_6) , 
and one is selected. As shown in the flowchart , the process of finding the appropriate 
ste1ilization methods is also an iterative one. 
Afte r a sterilization method is determined , the method is analyzed for particulate 
contaminant s (RD_7). If the level of particu late contaminant s excee ds the level allowed 
by the FDA, a new sterili zatio n method is determined. Otherwi se, biocompatibility tests 
(RD_8), identification of storage criteria (RD_ IO), and identifi cat ion of packaging 
materials (RD_ ! I) are then performed concurre ntly. After biocompatibi lity tests are run, 
failure-mode-effect ana lysis is perform ed (RD_9). If discouraging results are produced 
by this analysis, the requirements for the biomedical device com ponents need to be 
reana lyzed (RD_ I) . The packag ing materia ls are also eva luated (RD_ l2 ), and if found 
unsuitab le, the ident ification of appropriate packaging material s (RD_! I) is performed 
again. 
The MFG phase is initialized with the construction of a preliminary GMP 
manufac turin g faci lity (MFG_ !). Then, alternate vendo rs are identified and qua lified to 
assure the highest qua lity of raw material is acquired (MFG_2). After that, new and more 
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sophisticated equipment is added into this facility (MFG_3). At this point , it is important 
to note that the precedence for the next task of estab lishing a formal production process 
(MFG_ 4) are all of the tasks involved in dete1mining biocompatibility , storage criteria, 
packaging , and equipm ent. Thi s is followed by detem1ination of batch size and 
frequency of manufacturing (MFG_5). Then , each step of the production process is 
discussed with the research team to verify the process (MFG_6). ff a problem is found 
within the propo sed production process, an effort is made to revise the new production 
process until one can be finalized and implemented. Otherwise, new techniques and 
equipment for scale-up manufacturin g are proposed (MFG_7). All biomedical device 
components are then manufactured in batches (MFG_ 8). Next, the biom edical device 
components are assembled (MFG_9) and tested (MFG_ I0). This process is iterated until 
high quality biomedical device components are manufactured. Then , all of the 
components are assembled to form the final product (MFG_ ! I) and tested (MFG_ I2). 
Once the final product passes all tests, the biomedical device processing events are 
validated to ensure consistent processing (MFG_ l3). Then environmental controls are 
checked to ensure that they follow federal and state government regulations (MFG_ 14). 
At this point , the FDA REG process is begun. An Investigation Approval (IA) is 
filed and submitt ed to an Institutional Review Board or !RB (REG_ !). This documen t is 
revised until it is approved by the !RB. Then, followin g approval, an lnvestigational 
Device Exemption (LDE) is submitted to the FDA (REG_2). This docum ent is also 
revised until approv ed by the FDA. Clinical testing is then perfonn ed (MFG_l5) and a 
Premarket Notification (PMN) is submitted to the FDA (REG_3). If not approved by the 
FDA, the process could be repeated at the Product Deve lopment phase (ReRD) , Process 
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Development phase (ReMFG), or at clin ica l testing (ReMFG _ 15), as depicted in the 
flowchart of Figure 5. For exa mple, if problems are detennined by the FDA to be in the 
product development stage (ReRD), it may be possible that the probl ems arc related to 
the raw materials (ReRaw), production assembly process (ReProd), ster ilization method 
(ReSterilization), or biocompatib ility (ReB iocompatibi lity). If problems are determined 
by the FDA to be in the process development stage (ReMFG), it is possible that the 
problems are related to the production process (ReProdProcess), actua l manu facturi ng 
(ReManufacture), or enviro nm ental controls (ReEnvironment). After correcti ng the 
problems, the PMN is resubmitted to the FDA. Upon final approval by the FDA, the 
biomedical device is ready to be manufactured in full-scale for mass market 
(PREP MARKET). 
All tasks that have labels that begin with "Re" represent Phantom Repeat Tasks 
and Repeat Tasks as shown in Figure 6. Repeat Tasks are activities that may have to be 
repeated due to failure. These tasks do not have durations but probabi lities assigned to 
them, representing the probabilities of activity failure. Phantom Repeat Tasks are tasks 
that are used as logical loops back to earlier in the simulation model to different Task 
Groups and Primary Tasks when the application is rejected by the FDA. Therefore, like 
Repeat Tasks, Phantom Repeat Tasks also do not have durations but probabilities 
assigned to them, to represent the probabilities of these logical loops occuri ng. The FDA 
may reject the application for Premarket Notification (REG _3) due to various reasons, 
and therefore, action needs to be taken to correct these probl ems before resubmitting the 
application to the FDA. In order to mod el these, Phantom Repeat Tasks are used. For 
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example, it was determined that the FDA may reject the PMN due to problems either in 
the RD or MFG phases. These are represented by the labels , "ReRD" and "ReMFG." 
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Figu re 6: Phantom Repeat Tasks Flow at Product Development (RD), 
Within the RD phase, it is possible that the problems lie either within the Primary 
Tasks of "Identify Raw Materials (Raw)", "Determine Production Assembly Process 
(Prod)", "Determine Sterilization Method (Sterilization)", or "Determine 
Biocompatibility (Biocompatibi lity)" (Figure 6). These are represented by the labels, 
"ReRaw ", "ReProd", "ReSterilization ", and "ReBiocompatibi lity". If a task within 
"ReProd" is repeated, tasks within "ReSteri lization" and "ReBiocompatibi lity" are also 
repeated. After tasks within "ReBiocompatibi lity" have been completed, there are 
probabilitie s that tasks within "ReComponents" or "ReProdProcess" need to be repeated. 
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Otherwise, an app lication for PMN is sub mitted again to the FDA, represented by 
"RePMN " . 
The FDA may also determi ne that the problems lie in the MFG phase , as shown in 
Figure 7. Within this phase, there is probability that tasks within "Estab lish Final 
Production Process (ProdProcess)", "Ma nufactu re, Assemble, and Test Biomedica l 
Device Components (Man ufactu re)", or "E nsure Environm en tal Controls Follow 
Regulation s (Environ ment)" need to be repeated. These are represe nted by the labels, 
"ReProdProcess", "ReMa nufacture", and "ReE nvironm ent". After repeating 
"ReMan ufacture", there are possibilities of repeating tasks within "Re Manufa cture" again 
due to repeated performance fai lure, proceeding and repeat ing tasks within 
"ReEnvironment" or res ubm ittin g application for PMN approval, through "RePMN. " If 
tasks wi thin ReEnvironment are repeated, there is a poss ibilit y of resubmitting for 
Inve st igational Approval, "Re !A" or resubmitting for PMN approva l, "RePMN". 
r - - -
I ReMFG I 
Prob (X1) _______ :-=r ~ : b(X::ir ----- ~~ob (X4) 
_ Prob (X2) , r-------, --------
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Figure 7: Phantom Repeat Tasks Flow at Process Development (MFG). 
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Once Primary, Secondary, Repeat , and Phantom Repeat Tasks within the RD and 
MFG phases have been identified, it is nece ssary to ensure cons istency of the nowchai1 
with the simulation model that will be built. In SLAM 11 simulation networks, tasks are 
represented by ACTIVITY symbols. These symbols arc shaped like arrows. In order to 
reduce confusion while using the developed flowchart to create the simulation network 
model, it is useful to number each arrow prior to a task in the flowchart (Figure 8). 
Although the first task does not have an arrow before it, it is essential that a number is 
assigned and placed before the first task to denote an ACTIVITY flow. Therefore, these 
numbered arrows now represent the tasks for project planning. The characteristics of the 
ACTIVITY nodes include durations of tasks, probabiliti es of failed tasks having to be 
repeated, or probabilities of successful tasks. The durations of the tasks were estimated 
earlier in Section 4.5. 
The estimated probabilities of potential Repeat Tasks will be detennined in the 
next step. Due to the variabilit y of the task flow, and constant modification to the 
flowchart, it is not always possible or convenient to use sequentia l arrow numbers. It is, 
therefore, not nece ssary to emphasize the use of sequent ial task flow numbers in the 
flowchart. As may be seen later in the simulation network model, some of these numbers 
will not be utilized if deemed unneces sary. 
It is important to note that the ACTIVITY numbers in the simulation model must 
correspond with the task arrow numbers within the flowchart to ensure compatibility 
between the model and the flowchart. Again, as may be viewed later in the simu lation 
network model, there will be situat ions where arrow task number s have to be added 
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Figure 8: General Biomedical Device Product and Process Development Flowchart with Task Numbers (Cont.). 
simu lation network mod el. When a situat ion like this occurs, all ACTIVITY symbols 
relating to that task arrow will be given the same number. This usually occurs when the 
probability and duration for a single task has to be shown as two separate ACT IVITY 
symbo ls in order to facilitate repetitive tasks. There may also be case s where the 
flowchart may show separate task arrows for multipl e ent ity routes but the simu lation 
network model may need only one route, with the entity passing through it repeatedly. 
4.10 Estimate Probabilities of Potential Repeat Tasks and Phantom Repeat Tasks 
One of the uniqu e advantage s of using simulation for project plaiming is the 
ability to repre sent Repeat Tasks and Phantom Repeat Tasks, and to assign uncertainties 
or probabilities to them. In most project planning and manag ement software currently on 
the market , this is not possibl e. For proj ect planning purposes, the prob abiliti es of 
repeating tasks can be easily modified to decrease as more repetitions occur. This 
provides the project plaimer with the distinct advantage of justifying necessary changes in 
the project plan, as well as estimating the number of times a task will be repeated even 
before beginning the project. 
For simu lation modeling purposes, these prob abilities can be detennin ed by 
referencing histor ical data, speaking to people directly involved in the tasks, and by 
making logical assumptions. The se probabilities can be shown directly on the flowchart, 
in the simu lation model, or in a separate table with the corresponding task arrow numb er. 
For space conservation , the probabilitie s are show n directly in the simulation model , and 
not in the flowchart. 
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4.11 Develop Simulation Network Model 
The project planning netwo rk for biomedical device process development and 
manufactur ing utilizes a var iety of nod es and symbo ls ava ilabl e in the SLAM II 
language. They includ e the ASS IGN, ACCUMULA TE, COLCT, CREATE, GOON, 
TEXT and T ERMINATE nodes, as wel l as the ACTlVITY sym bol s. Except for the 
TEXT nodes, genera l combinati ons of these nodes and symbo ls hav e been developed in 
th is research to accommodate biomedica l dev ice project planning purposes. Th e TEXT 
nodes are exc luded from these com bin ations because they do not affect the runnin g of the 
simu lation, and are on ly used as "ca pti ons" to iden tify tasks. Each genera l comb inatio n 
is called a subnetwork. A proj ect planner can either use these sub networks to deve lop 
custo mized s imulatio n network mode l to pla n for biomed ical device product and process 
deve lopment or use the general simu lation network model developed in Sec tion 4.11.5 , 
and modify the mode l to accommodate project uniqu eness. Examp le appli cation s of 
these subnetworks are presented in the follow ing sect ions. 
4.1 I.I "START OF PROJECT" Subnetwork 
CREATE and COLCT are the basic nodes and ACTIV ITY is the basic symbo l 
used to model the start of a project (Figure 9). The main function of the CREA TE node is 
to genera te entities to be routed into the network. 
CREATE ACT IV ITY COLCT 
Figure 9: "START OF PROJ ECT" Subnetwork. 
61 
An appl ication o f the "START OF PROJECT" subnetwork is shown in Figure 10. 
For project plmming purpo ses, the time of the first created entity is 0.0, show n above the 
squ iggly line before the CREATE node. For project plannin g networ ks, only one entity 
is created. Th ere fore, the time betw een arriva ls is 0.0, denot ed above the top curve. The 
value for the maximum number of creations is also set at I, as shown in the lowe r left 
section of the CREA TE node. Similarl y, the maximum numb er of entiti es to be routed 
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Figure 10: "START OF PROJECT" Subnetwork Application. 
Each Primary or Secondary Task is represent ed by an ACTIV ITY symbo l and has 
a specified duration , condi tion, or both. The duration specifics a time delay for an entity 
moving through that act ivity. For project plannin g purposes , the value of the duration 
and condition is set as a constant or as a SLAM II random var iable . For the "START OF 
PROJECT" subnetwork in Figure I 0, the first task is "Determin e Biom edical Device 
Components". The ACTIVITY symbo l utilizes the data co llected in Section 4.5. 
Therefo re, the SLAM 11 random variab le of a triangular distribution with a maximum , 
mode and min imum value, or TRIAG(X,Y,Z), is used as the durat ion for proj ect 
planning. The ACTIVITY number , corresponding to the task arrow numb er in the 
deve loped 0owchart is represente d as " 1" withi n the ACTIVITY symbo l. 
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In project planning , some of the most important performance measures are the 
estimated start time of a certain task and the project 's estimated completio n time. The 
COLCT or Collect Node is used to compile the estimated start times for each 
predete1111ined task, as well as the estimated overall project completion time. In order to 
obtain an estimated earlies t completion time for the "Detennin e Biomedical De vice 
Components" task , FIRST ARRIVE is used in the first column of the COLCT node 
(Figure 10). In SLAM II, the estimates for the mean and standard deviation values of 
these observa tions are automatically recorded and prese nted in the output summary. The 
second column of the COLCT node requires an identifier. It is recommended that 
predete1111ined task names always be used as inputs for the identifier column. This 
enab les each COLCT node to be later identified in the output summary by its task name. 
In the third column, " I" represents the maximum number of entities allowed to exit the 
COLCT node. This number is genera lly "I", except for cases where an entity is divid ed 
into two or more entities to simulate activities being performed concurrently. 
It is also very important for the project planner to be able to easily manipulat e the 
variables and probabilities set for the differ ent tasks. For example, it is usually necessary 
to represe nt the probability of a task being rework ed a third time to be of a lesser value 
than the probability of the task having to be performed the second time. Therefore, it 
may be necessary to differentiate an entity arriving into the system for the very first time 
that has to flow through all tasks , from an entity that is looped back to simulate a Repeat 
task. The "START OF PROJECT WITH ENTITY ASSIGNMENT" subnetwork (Figure 
11), shows a particularly useful combination of CREATE, ASSIGN, GOON, and 
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COLCT nodes as well as ACTIVITY symbol s. The ASSIGN nod e is utilized when there 
is a need to set a value for an attribute of an entity passing through it. 
CREATE ASSIGN GOON COLCT 
ACTIV ITY ACTIV ITY ACTIVITY 
Figure 11: "START OF PROJECT WITH ENTITY ASSIGNMENT" 
Subnetwo rk. 
In order to ass ign and diff erentiate these task s, the ASSIGN node in "START OF 
PROJ ECT WITH ENTITY ASS IGNM ENT" subnetwo rk is given the criterion o f 
A TRIB[ I] with the actual numerical value of I (Figure 12). A TRIB [ I] , therefore, 
represents the type o f arriving entit y and the actual num erical value of I represents an 
entity nowing through the task from the very beginnin g of the project. 
The GOON node functions as a separator of tasks (Figure 12). It is used to link 
tasks that are sequential. It is also used when a single task is followed by seve ral tasks 
that need to be performed simultaneously, in which case the va lue of the GOO N node 
will be the number o f those tasks. The GOON nod e is also utili zed whenever there is a 
poss ibility that a task may be repeated due to failure. It is recomm ended that if the 
GOON node is used as a link for repeated activities, a "Re" be added to the front of the 
label to signify this use in the netwo rk model. 
R0_1 
TRIAG (X,Y,Z 
>--- -+I FIRSTARRIVE 




Figure 12: "START OF PROJECT WITH ENTITY ASS IGNMENT" Subnetwo rk 
Application. 
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4.11.2 "COLLE CT ACTIVITY AND REP EA T ACTIVITY INFORMATIO N" 
Subnetwork 
The "COLLECT ACTIVITY AND REPEA T ACT IVITY INFORMATION" 
subnetwork consists of GOON and COLCT nodes, as we ll as ACTIVITY symbols. 
Some of the ACTIVITY symbols represent Repeat Tasks (Figure I 3). This comb ination 
is useful when there are sequential tasks and probabilities ofrepeating tasks. 
GOON COLCT COLCT 
ACTIVITY ACTIVITY ACTIVITY 
Figure 13: "COLLECT ACTIVITY AND REPEAT ACTIVITY INFORMATION" 
Subnetwork. 
For example, in the general biom edical device product and process deve lopment 
flowchart, the task, "Research and Specify Raw Materials for Biomedical Device" is 
followed by the task, "Test for Suitab ility of Raw Mater ials for Biomedica l Device." As 
noted in the flowchart , there is a possibility that the chosen raw material may fail the test, 
and the task , "Research and Spec ify Raw Materia ls for Biomedica l Devic e" will have to 
be repeated. Thi s application is shown in Figure 14. Figures 15 to 18 show other 
applications of the "COLLECT ACTIVITY AND REPEAT ACT IVITY 
INFORMATION" subnetwork. In order to collect the number of times a task is repeated , 
an additio nal COLCT node is used between the Repeat ACTIVITY symbo l and another 
ACTIVITY symbo l directing the entity to a "Re" node. It is recommen ded that the 
project planner use these COLCT nodes only when necessary to avoid simulation 
network clutter as well to avoid over loading the computer memory space durin g the 
running of the simulation. 
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Figure 14: "COLLECT ACTIVITY AND REPEAT ACTIVITY INFORMATION" Subnetwork Application I. 
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Figure 15: "COLLECT ACTIVITY AND REPEAT ACTIVITY INFORMATION" Subnetwork Application 2. 
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Figure 16: "COLLECT ACTIVITY AND REPEAT ACTIVITY INFORMATION" Subnetwork Application 3. 
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Figure 17: "COLLECT ACTIVITY AND REPEAT ACTIVITY INFORMATION" Subnetwork Application 4. 
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Figure 18: "COLLECT ACTIVITY AND REPEAT ACTIVITY INFORMATION" Subnetwork Application 5. 
4.1 J.3 "SPLJT ACTIVITY" S11b11etwork 
The "SPLIT AC TIVITY" subnetwork con sists o r a GOON or COL CT node, and 
multipl e AC TI VITY symb o ls . Th ese combination s are co mmonl y used lo cause an entity 
to divide and now in separate paths simultan eou sly to simul ate con curre nt tasks being 
perfom1ed ("SP LIT AC TIVITY -SIM ULTA NEOUS FLOW" subn etwork) , to dir ect an 
entit y lo a ce rtain path due to a predelennin ed probabilit y or the entity takin g that path 
("S PLIT ACTI V ITY-PR OBABILI STIC FLOW" subn etwo rk) , or to dire ct an entit y to a 
certain path due to its allr ibul e ("SPLIT AC TIVIT Y-ATTRIB UTE FLOW" subnetwor k). 
These diff erent subnetwo rks are show n in Figures 19 to 2 1. Exa mpl e appli cation s for 
these subn etwo rks are show n in Figures 22 to 27 . 
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Figure 21: "SPLIT ACTIVJTY-ATTRJBUTE FLOW" Subnetwork. 
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Figure 22: "SPLIT ACTIVITY-SIMULTANEOUS FLOW" Subnetwork 
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Figure 25 : "SPLIT ACTIVITY-PROBABILISTIC FLOW" Subnetwork 
Application 2. 
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Figure 27: "SPLIT ACTIVITY -ATTRIBUTE FLOW" Subnetwork Application 2. 
4.11.4 "ACCUMULATE ACTIVITY" Sub network 
In project planning, certain tasks commonly need to be performed before starting 
another task. This is model ed using the "ACCUMULATE ACTIVITY" subnetwork. 
The "ACCUMULATE ACTIVITY" subnetwork consists of seve ral ACTIVITY symbols 
entering a single ACCUMULATE node (Figure 28). The ACCUMULATE node is used 
to route one exiting entity from a group of incoming entities. Therefore, in project 
planning, it is only when a defined number of preceding tasks have been completed that 




Figure 28: "ACCUMULATE ACTIVITY" Subnetwo rk. 
The value in the top-l eft sectio n of the ACCUMULATE node determ ines the 
required number of incoming entities to release the node for the first time whereas the 
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value in the bottom left sect ion of the ACCUMULATE nod e specifics the number of 
incoming ent ities required for subsequent releas es (Figure 29). The criterion "LAST" , 
located in the cen ter of the node, specifics that the attributes of the last arriving entit y be 
given to the entity that is routed from the node. Therefore , this criterion stores the time 
value for the last arriving entity to that node. A single exiting entity is represented by 
setting the maximum numb er of outgoing branches, located in the right-most co lumn of 
the ACCUMULATE node , at "I." 
FIRST ARRIVE "Perfom, Failure-Mode-Effect-Analysis" 
"Evaluate Packaging Material" 
RD_12 
Figure 29: "ACCUMULATE ACTIVITY" Subnetwork Application. 
4.11.5 "END OF PROJECT" Subnetwork 
The "END OF PROJECT" subnetwork is a combination of the final ACTIVITY 
symbol(s), a COLCT node and a TERMINATE node (Figure 30). This combinati on is 
used at the end of a simulati on network model. 
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ACTIVITY COLCT ACT IVITY TERMINATE 
Figure 30: "END OF PROJECT" Subnetwork. 
SLAM II has the capability of providing the output data in the form of a 
hislogra rn report . In order to obtain a histogram report in the output summary , it is 
necess ary to defin e this option in the final COL CT node. From the histogram report , it is 
poss ible to determin e the estimate d probabilit y of a proj ect being completed in a certain 
durat ion. ll is also poss ible to determin e the relative frequency of proj ect compl etion 
times, given seve ral run s. 
The TERMTNATE node functions to delete entiti es from a projec t plan. Since 
one entity was crea ted for a proj ect simul ation run , onl y one entity should be terminated 
a fter every run. Therefore , the total count of entiti es exiting this node is set at "I" (Figure 
3 I) . 
4.11.6 TEXT Node 
The TEXT node is used to match tasks with their duratio ns. Therefore, this node 
is usually placed abo ve the AC TIVITY node, and is provided the labels specified in 
Co lumn 4.4 of Tab le 5. The labels within thi s co lumn are used beca use they captur e each 
task within the biom edica l device produ ct and process deve lopme nt. The use o f this node 
does not affec t the running o f the simulat ion mod el. 
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"Biomedical Devic 
FIRST ARRIVE Ready For Market" 1 
30/100110 
READY MARKET 
Figure 31: "END OF PROJECT" Sub network App lication . 
4.11. 7 Example Combinations of "COLLECT ACTIVITY AND REPE A T 
ACTIVITY INFORMATION" and "SPLIT ACTIVITY" Subnet>Vorks 
Various combinations of "COLLECT ACTIVI TY AND REPE AT AC TIVITY" 
and "SPLIT ACTIVITY" subnetwork s are used to assi gn differen t probabiliti es to 
diff erent task s dependin g on the attribute of that entity. For example, if an application 
has been submitted for Premarket Notificatio n and denied by the FDA due to a Research 
and Developm ent probl em, the entity is ass igned A TRIB[ 1 ]~2, and is repeated at 
"ReRD". Simi larl y, if the application wa s denied by the FDA due to a Manufacturin g 
problem , the entity is assigned ATRIB[ l ]~3, and is rep eated at "ReMF G." As the entities 
are rerouted back to repeat the problem task s, the probabilities of task rep etition can be 
easi ly manipulated by using ASS IGN nod es with variabl es that repr esen t these 
probabilities. An exam ple application of this can be seen in Figure 32 and Figure 33. 
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Figure 32: Example Combination of "COLLECT ACTIVITY AND REPEAT ACTIVITY INFORMATION" and "SPLIT 
ACTIVITY" Subnetworks I. 
f----- -->IATRIB[1]= 1 
[ill] 
PROB (XX [61) 
fill 
FIRSTARRIVE "ReRawFrRe RD~ 1 
ITypeRDI I RepeatRaw I 
PROB (XX [SJ) FIRST ARRIVE "RePmdF,ReRO' 1 
li"1l 
I RepeatProd I 
PROB (XX [71) 
FIRSTARRIVE "ReSteril izationFrReRD" 
~ 
Repea tSterili zation 
PROB (XX [81) 
I@ 
FIRSTARRIVE "ReBiocompatibilityFrReRD" ReBiocompatib ility 
I RepeatBiocompatibility I 
PROB (XX [91) 
Ifill 
FIRSTARRIVE "ReManufactureFrReMFG" 1 , IReManufacturel 
PROB (XX [10I) FIRST ARRIVE "ReEnsimnmen tF,ReMFG' 1 
~ 
ReEnvironmen t 
PROB (XX [Ill) FIRST ARRIVE "RePmdPmce ss" 1 IReProdProc ess l 
\Repea tProductionProcessl 
Figure 33: Example Combination of "COLLECT ACTIVITY AND REPEAT ACTIVITY INFORMATION " and "SPLIT 
ACTIVITY" Subnetworks 2. 
4. I /.8 General Biomedical Device Produ ct anti Process De,1elopm e11t Simulation 
Netwo rk Model 
The sim ulation network model was developed based on the information from the 
previous nowchart (Figure 8) for genera l biomedical device product and process 
development. An overv iew of the simulation network model for genera l biomedical 
device product and process development is show n in Figure 34. Figure 35 shows an 
exploded version of the simulation network model. The product planner may choose to 
develop a new simu lation network from scratch utilizing the BOPP methodology and the 
provided subnetworks or modify the ge neral biomedical device simu lation network 
model to fit the uniqu eness ofa biomedica l device. A detailed example application of the 
genera l biomedica l dev ice product and process development simulation network model 
template is addressed in Chapter 5. 
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~ Figure 34: Simulation Network Model for General Biomedical Device Product and Process Development - Overview. 
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Fieure 35: Simulation Network Model for General Biomedical Device Product and Process Development - Exp lod ed (Cont.). 
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Figur e 35: Simul ation Network Model for General Biom edica l Device Produ ct and Pro cess Developm ent - Exploded (Co nt .). 
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:g Figure 35: Simulation Network Model for Gen eral Biom edical Device Product and Process Development - Exp loded (Cont.). 
4.12 Develop Simu lation Control Statements 
Following lhe creation of the simulation network_ model, the simula tion Control 
Sta teme nts are deve loped. There are six basic co ntrol statements for project planning. 
They are GEN , UM ITS, INTLC, INIT IALIZE, NETWORK, and FIN. Th ese stateme nts 
are show n in Figure 36. In the GEN state ment, the inputs includ e the name of the project 
planner, the titl e of the proj ect, the date the project is created, and the number of runs. 
The rest of the GEN sta tem ent, "Attempt Execution" and "Warn of Destroyed Entities", is 
left defaulted at "Yes." 
GEN,"Project Planner Name","Ge nera l Biomedica l Device Product and Proc ess 
Deve lopment", Da te, Ml, YES, YES; 
LIMITS , l l ,,,3; 
INTLC , ( {XX[!], XI },{XX[2], X2),{XX[3], X3},(XX[4], X4) {XX[5], X5),{XX(6], 
X6), {XX[7], X7},{XX[8], X8),{XX[9], X9},{XX(I0], XI0},{XX[l 1], XI I)}; 
INITIALIZE ,0.0, M2,NO,,YES; 
NETWORK,READ; 
FIN; 
Figure 36: Simulation Co ntrol State ments for General Biomedical Device Product 
and Process Development. 
Th e most important input in the GEN Statement is the number of run s of the 
s imulation model, Ml. This input determ ines the number of replications for simulatio n 
as we ll as the accuracy of the results. Kelto n et al. ( 1998) recommend that an initial set 
of replications, no, is made in order to obta in a sample average , X, a sta ndard deviation, s, 
and a con fidence interval with a half-width, h0. The following formu la is used to 
calculate ho: 
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where r is the I-statistic with 11 - I degrees of freedom and a probability leve l of/ - a /2 . 
It is recommend ed that the mod el 11rst be simul ated for 20 run s. Having analyzed 
the resu lts to obtain a con11dence interval with a certain half-width , the projec t planner 
may choose to increase or reduce this half-w idth if deemed necessary to obtain more 
desirable results. Thi s will require a manipulation of the number of runs in the 
simulation. The fomrnla to detennine the required number of runs to achieve a certain 
half -width in a con11dence interval will be shown in Section 4.14. 
The LIMITS statement (Figure 36) allows the project planner to set the ma ximum 
allowable limits for global variables and attrib utes. Since the simulation model for 
general biomedical device product and process developm ent plannin g contains eleven 
XX[] global variables and three A TRIB[] attribute var iables, the input s for the maximum 
allowable limits for these variables are 11 and 3, respectivel y. 
The fNTLC stateme nt assigns initial values to the XX[] global variab les. Since 
these global variab les are used in the simul ation model to repr esent the possibility of 
repeating tasks, the va lues for these variab les are set accordin g to the probability of 
repeating thos e task s for the 11rst time. For example, the proj ect planner can give the 
globa l variab le, XX[ !] a probability of XI. 
In the fNTLC statement, the variab les, XX[!], XX[2], XX[3], and XX[4] 
represe nt the initial probabilities of loopin g back in the simulation model from the 
submi ssio n of PMN (REG _3) to the clinical testing (ReMFG _ l9) task , the Manufacturing 
phase (ReM FG) and the Research and Deve lopment pha se (ReRD) , respectively. The 
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var iables, XX[5], XX[6], XX[7], and XX[S] rep rese nt the charac teristics of an en tity that 
is looped back to the "ReRD" phase (ATR IB[1 ]== 2) and variables XX[9], XX[I0], and 
XX[ 11] represe nt the charac teristics of an entit y that is loope d back to the '"ReM FG" 
phase (ATRIB[ I ]== 3). Th erefore, the va riables, XX[5], XX[6] , XX[7 ], and XX[S], 
represent the initi al probabiliti es of looping back from the submi ssion of PM N (REG _ 3) 
to the detem1inat ion of raw mat erials (R eRaw ), the detennination of product asse mbly 
process (ReProd), dete nnination of ste rili zation method (ReSterilization) , and 
detennination of biocompatibility (ReBioco mp atibility). The var iables, XX[9], XX[ ! OJ, 
and XX[! I] represen t the initial probabiliti es of loopin g back from the submi ssion o f 
PMN (REG _3) to the manufacturing, assem bling , and test ing of b iomedical dev ice 
components (ReManufacture), detem1ination of environmenta l controls 
(ReEnvironment), and detem1ination of forma l produ ction process (ReProdProcess). 
Th e INIT IALIZE Statement (Figure 36) is used to set th e beginning and endin g 
times for each simulation run. Since the simulation network model was created to start at 
time 0.0, the begin time of the simulation run is set to be 0.0. The end time of a 
simulation run, M2, differs from project to project and is obtained using trial and error. 
The project planner shou ld set this tim e by estim ating the longes t amount of time the 
whole projec t could possibly take. If the simu lat ion run takes longe r than this input , the 
results will either give an error during the simu lation run, or give no data at all in the final 
few COLC T node results. Therefore, the proje ct planne r can modify the IN IT IALI ZE 
statement to lengthen the simulation run. The project planner should choose "No" in the 
"Clear Statistics Between Runs" sec tion . This wi ll provide the project planner with the 
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average results of all the runs and will provide a histogram report of all runs that can be 
used for further analysis. 
The NETWORK and FIN Statements must be included to run the mod el. The 
NETWORK Statement is defaulted at option "READ." The FIN Statement does not 
require any input from the projec t planner and merely specifies the end of the CONTROL 
statements. 
4.13 Run Si mul ation Mo del 
Onc e the input for the Control Statement has been completed, the simulation 
model is run. As mentioned in the prev ious section, it is recommended that the mode l 
first be simulated for 20 runs. After analyzi ng the results of these 20 runs , depending on 
the desired accurac y of the results, mor e runs may be made to reduc e the half-width 
confidence interval. 
4.14 Ana lyze Res ults 
The simulation results will provide a summary of the requ ested runs. Figure 37 
shows an example of the AweSim Summary Report for the general biom edical de vice 
product and process de ve lopment simulation network model developed previously . The 
Summary Report includes the day, date, time and year the report is print ed, the title of the 
simu lation project, the name of the project planner or mode ler, the date the model was 
created, the name of the scenario, number of runs, current simulation time , and the tim e 
that the stati stics were last cleared. Within the Observed Statistics Report section of the 
Summary Report are the task label s, averag e acro ss all runs of the mean values, standard 
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** AweSim SUMMARY REPORT ** 
Day Date Time Year 
Simu lation Proj ect : Ge neral Biomedic.tl Device Product and Proces s Development 
Modeler: Project Planner 
Dat e: 
Scenario : BASE CASE 
Run numb er M of i\11 
Curr ent simulation tim e: 
Statistics clea red a t tim e: 
** OBSERV ED STATIST ICS REPORT for scenario BASE CASE ** 
Label 
Mean Standard No. of M inimum Maxi mum 
Valu e Deviatio n Observat ions Value Val ue 
Determine Biomedical Device 
Compo nents 
Research and Specify Raw 
Materials for Biomedical 
Device 
Test for Suitability of Raw 
Mater ials for Biomedical 
Device 
Determine Produ ction 
Assemb ly Process 
Determine Sterilizat ion Method 
Analyze Effects of Sterilization 
Analyze Particulate 
Contaminan ts 




Identify Storag e Criteria 
Ident ify Packaging Material 
Evaluate Packaging Material 
Construct Preliminary GMP 
Manufactur ing Facility 
Figure 37: Results of Simul ation Run - Observed Statis tics Sect ion. 
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Mean Standan l No. of Minimum Max imum 
Labe l Va lue Deviat ion Observ ation s Valu e Va lue 
Identify and Qualify Alternate 
Vendo rs 
Insta ll New Equipment 
Establish Formal Produ ction 
Process 
Determine Batch Size and 
Frequency of Manufactur ing 
Discuss with Research Team 
and Confi rm Each Step of 
Productio n Proce ss 
Propo se New Techniques and 
Equipment for Scale-Up 
Manufacturinf! 
Manufacture Biomedical 
Device Component s 
Assemb le Biomedi ca l Device 
Componen ts 
Test Biomedical Device 
Compone nts 
Assemble Final Produ ct 
Test Final Produ ct 
Validate Insulin Pump 
Processing Events 
Ensure Environm enta l Contro ls 
Follow Regulation s 
File For lnvestigational 
Approva l by !RD 
Submit lnves tigational Devi ce 
Exemp tion to FDA 
Perform Clinical Testing 
Submit Prema rket Notificat ion 
SIOK 
Prepare Biomedical Device For 
Market 
Biom edic al Device Ready for 
M ark et 
Figur e 37: Result s of Simul ation Run - Ob served Stati stics Section (C ont .) 
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Mean Standard No. of Min imum Maximum 
Label Value Deviation Observations Value Value 
ReMFG l lFrMFG 12 - -









Figur e 37: Results of Simulation Run - Observed Statistics Section (Cont.) 
deviations, and number of observations, as well as the minimum and maximum time 
values collecled by the COLC T nodes in the simulalion network. 
The "Mean Value" column (Figure 37) provides !he average complet ion time for 
each task. The 11Standard Deviation" column provides the standard deviation for each 
task. The "No. of Observat ions" column denotes the number of times each task is 
perfonned. If a COLCT node was used to collect the observations for a Repeat Task 
from a particular task, the number of times the task is repeated is included within this 
column. For example, in the general simulation network model, the COLCT node with 
!he identifier of "ReRawFrReRD" will provide !he number of times an enlity flows 
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between "ReRaw" and "ReRD." Therefor e, it denotes the number of times the entity 
arrives from "ReRD" to "ReRaw" to be repeated. 
The results of the last run will provide a histogram repo,1 that is useful for 
analysi s. Throu gh this histogram report , it is possible to detennin e the probability of a 
task bein g completed by a certain time. 
Since only one ent ity was created in the CREATE node , only one entity shoul d 
exit the simulation system . Therefore, the numb er of obse rvatio ns for the final COLCT 
node, "Biomedical Devic e Ready For Market" should equal the total number of runs 
specified in the GEN statement within the Contro l Statem.cnts. The gray area in Figure 
37 should be checked for this equality after each simu lation run. 
If the half -width of the confide nce interval is considered too large, a new half -
width, h, is chosen. The follow ing fonnu la is used to estimate a more appropriate sample 
size, 11: 
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CHA PT ER 5 
EXAMPLE A PPLI CAT IO N 
This chap ter describ es the plannin g and manage ment of a project to develop an 
exte rnal insulin pump , using the methodology describe d in the previous chapter. Th ere 
are two type of insulin pumps , imp lantable and external. The external insulin pump was 
chose n for this project due to the availab ility ofinfonnation on this biom edical dev ice. 
5.1 Co llect Data 
An extens ive litera tur e sea rch was conducted to ga ther infonnation on the 
functions, compone nts, product and proc ess develop ment methods, and FDA reg ulati ons 
related to the externa l insulin pump . Although suffici ent documenta tion exists regarding 
the functions and com pon ents of the insulin pump , no publ ic litera tur e was found 
detailing the product and process deve lopm ent of the pump. Therefore, the general 
biomedical device process deve lopm ent and ma nufactur ing model deve loped in the 
previous chapte r was used, along with pra ctica l experience gained while worki ng with 
these pump s. Experts in the insu lin pump manufacturing area were also co nsulted to 
provide and verify the inforn,ation needed to develop the proj ect plan. 
An insu lin pump is a high- technolo gy medical dev ice used for the treatment of 
insulin-de pendent diabetes. Users of exte rnal insulin pumps set "basa l" and "bo lus" 
doses of insulin . Insulin pumps are programmed to provide "basa l" doses conti nuou sly 
during the day , whe reas "bo lus" doses are given at mea l times and at times when blood 
sugar levels are extre mely high (Hitchcock, 2000). 
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An insu lin pump is attached to the hum an body through a cat heter (a nexibl e 
plastic tubin g) wi th a needle inserted under the skin near the abdomen. The pump is 
approx imat ely 2" x 3" x I " and weighs between 3 and 6 ounces. Typical top-level insulin 
pump comp onen ts include a so lenoid motor, pump case, window panel, electronics boa rd 
or microcomputer and comput er software, mechani ca l driver ann, lead screw, reservoir 
converter, luer neck leve r, batt ery compa rtment , and syrin ge, as shown in Figures 38 and 
39 (M inim edTM Use r's Guide; J. Livingston , personal communicat ion, June 19, 2000) . 
However, the loca tions of the so leno id motor and electron ics bo ard were approximated 






Figure 38: Front View of an Exte rnal Insulin Pump. 
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'----- - --· _______ ' 
Figure 39: Back View of an Open External Insulin Pump. 
5.2 Determine Task Groups 
As recommended in the BOPP methodology, the major Task Groups were 
determined to be in Product Development or Research and Development (RD) , Process 
Development or Manufacturing (MFG), and Regulatory (REG) , as shown in Column 5.2 
in Tab le 6. 
5.3 Determine Primary Tasks 
The Primary Tasks in the general flowchart developed in the methodol ogy were 
considered applicable for the product and proce ss deve lopment of an insulin pump . 
Therefore, the same Primar y Tasks were utilized and given uniqu e labels for easy 








Table 6: Insulin Pump Project Planning Task Grou ps and Pr ecedences Summar y. 
Pr imary T as k Second ary Task Dur ation (weeks) 
Primar y Tas k Seconda ry Tas k 
(5.3) (5.4) (5.5) 
Pr ecedence Pr ecedence 
(5.6) (5.7) 
Determine Insulin Pump None(RD_ I) 
TRJAG(4,5,6) 
Comoonents (Components) 
Identify Raw Materia ls Research and Specify Raw 
(Raw) Materials for Solenoid Motor TRJAG (2,5,6) Components 
/RD 2) 
Research and Specify Raw 
TRIAG(l ,3,6) Components 
Materials for Syringe (RD 3) 
Research and Specify Raw 
TRIAG(3,5,6) Components Materials for Pump Case (RD_ 4) 
Research and Specify Raw 
Materials for Window Panel TRIAG (2,3,5) Components 
(RD 5) 
Research and Specify Raw 
Materials for Mechanical Driv er TRIAG(4,6,8) Components 
Arm(RD 6) 
Research and Specify Raw 
TRIAG( 1,5,9) Compone nts Materia ls for Lead Screw (RD_ 7) 
Research and Specify Raw 
Materia ls for Reservoir Conve rter TR IAG(2 ,6,7) Component s 
(RD 8) 
Research and Specify Raw 
Materials for Luer Neck Lever TRJAG ( 1,4,9) Component s 
(RD 9) 
Research and Specify Raw 
Materials for Battery TRJAG (2,4 ,5) Compon ents 
Compartment (RD I 0) 
Table 6: Insulin Pump Project Planning Task Groups and Pr ecedenc es Summary (Cont.). 
Task Primary Task Secondary Task Duration (weeks) 
Primary Task Seco ndary Tas k 
Group (5.3) (5.4) (5.5) 
Prec eden ce Pr ece dence 
(5.2) (5 .6) (5.7) 
Develop Code for Software 
TRIAG(7 ,8,9) Components (RD_II} 
Test for Suitability of Raw 
Materials for Solenoid Motor TRIAG(J,5,6) RD_2 
(RD 12) 
Test for Suitabi lity of Raw 
TRIAG ( 1,4,5) RD_J Materials for Syringe (RD _13) 
Test for Suitability of Raw 
Materials for Pump Case TRIAG(2.4 ,5) RD_4 
(RD 14) 
Test for Suitability of Raw 
Materials for Window Panel TRIAG (J,4.8) RD_S 
8 (RD 15) 
RD Test for Suitability of Raw 
(Cont.) Materials for Mechanical Driver TRIAG( 1,4,8) RD_6 
Arm(RD 16) 
Test for Suitability of Raw 
Materials for Lead Screw TR!AG(J,5 ,6). RD_ 7 
(RD 17) 
Test for Suitability of Raw 
Materials for Reservoir Converter TRIA G(2,5.8) RD_8 
(RD 18) 
Test for Suitability of Raw 
Materials for Luer Neck Lever TRIAG(2.3 ,4) RD_9 
(RD 19) 
Test for Suitability of Raw 
Materials for Battery TRIAG (3,7,8) RD 10 -
Compartment (RD 20) 
Test Softwa re Code (RD 2 l) TRIAG(2,3,5) RD II 
Table 6: Insulin Pump Project Planning Task Groups and Precedences Summary (Co nt. ). 
Task Primary Tas k Secon dar y Task Duration (weeks) 
Pr imar y Ta sk Secondar y Task 
Group (5.3) (5.4) (5.5 ) 
Prec ede nce Pr eceden ce 
(5.2) (5.6) (5.7) 
Determine Production None (RD_22) 
TRIAG(S ,7.8) Raw 
Assemblv Process (Prod) 
/ 
Deterf11lne and Test Determine Sterilization Method 
TRIAG(S ,7,8) Prod 
Sterilization Method (RD 23) 
(Sterilization) Analyze Effects of Sterilization 
TRIAG(2.5 .6) RD_23 
(RD 24) 
Analyze Particu late Contaminants 
TRIAG(2,4,6) RD_24 (RD_25) 
RD Determine Biocompatibility Run Tests To Investigate TRIAG(l,5,6) Sterilization 
(Cont.) (Biocompatibility) Biocompatibility (RD _26) 
Perform Failure•Mode•Effect 
Ana lysis (RD _29) TRI AG(2,5,8) RD_26 
Identify Storage Criteria None (RD_27) 
TRIA G(l,2,3) Steril ization 
(Storage) 
Determine Packaging Identify Packaging Material 
TRIAG( 1,2,3) Ste rilization 
Material iRD 28\ 
(Packaging) Evaluate Packaging Material 
TRIAG(l ,2,J) · RD_28 (RD 30) 
Construct Preliminary GM P No ne (MFG _ I) 
Manufacturing Facilit y TRIAG(12.13 , 15) Prod 
(GM P) 
Identify and Qualify None (MFG_2) 
TRIAG(4,5,6) GMP 
Alternate Vendors (Vendor) 
MFG 
Install New Equipment None (MFG _3) 
(Equipment) 
TRIAG(3 ,4.5) V endor 
Establish Formal Prod uction Establish Formal Production Biocompat ibility , 









Table 6: Insulin Pump Proj ect Plannin g Task Group s and Pr ecedenc es Summar y (Cont. ). 
Prim ar y Task Second ar y Task Du rat ion (wee ks) 
Prima ry Task Secondary Task 
Precedence Precede nce 
(5.3) (5.4) (5.5) 15.61 15.7\ 
Determine Batch Size and 
Frequency of Manufacturing TRIAG ( 1,3,5) MFG_4 
(MFG 5) 
Discuss with Research Team and 
Confirm Each Step of Production TRIAG(2,3,4) MFG_S 
Process (MFG 6) 
Propose New Techniques and 
Equipment for Scale-up TRIAG(l,6,10) MFG _6 
Manufacturing (MFG 7) 
Manufacture, Assemble, and Manufacture Insulin Pump 
TRIAG(7,8, 12) Prod Process Test Insulin Pump Components (MFG_8) 
Components Assemble Solenoid Motor 
TRIAG(2,7,9) (Manufacture) (MFG 91 
MFG _8 
Test Solenoid Motor (MFG _ !O) TRIAG(l ,5,7) MFG 9 
Assemble Electronics Board 
(MFG_\!) TRIAG(2,5,6) \1FG _ IO 
Test Electronic Board (MFG 12) TRIAG(4,6,8) MFG 11 
Assemble Solenoid Motor and 
Electronics Board on Pump Case TRIAG( J,6,7) MFG 12 -
(MFG 13) 
Test Solenoid Motor and 
Electronics Board on Pump Case TRIAG ( 1,4,5) MF G_\3 
(MFG 141 
Assemble Final Product 
TR!AG (2,J,4) \1F G_ 14 
(MFG 15) 
Test Final Product (MFG 16) TRIAG (2,4,5) MFG 15 
Validate Insulin Pump Processing 
TRIAG( J,6,7) Events (MFG _17) MFG _ \6 
Table 6: Insulin Pump Project Planning T ask Groups and Preced ences Summar y (Cont .). 
Tas k Prim ary Tas k Secondary Task Dura tion (weeks) 
Primary Ta sk Seco ndary Ta sk 
Group (5.3) (5.4) (5. 5) 
Prec edence Pr ecedence 
(5.2) (5 .6) (5.7) 
Ensure Environmental None (MFG _ I 8) 
MFG 
Controls Follow TRIAG(3,5,6) Manufacture 
Rer!Ulations (Env ironmen t) 
(Cont.) 
Perform Clinical Testing None (M FG_ I 9) 
(C linical) 
TR!AG(5,8,9) IDE 
File for Investigational None (REG !\ TR!AG(4,6,7) 
Environment 
Approval from !RB (IA) WAIT TRIAG(2,3 ,4 ) 
Submit Investigational None (REG 2) TRIAG(5,7, 8) 




Submit for Premarket None (REG 3) TRJAG(3 ,4,5) 
Clinical Notification (PMN) TRIAG(S,9,10) 
Prepa re Insulin Pump For None (PRE PMARKET) 
TRJAG(2,3 ,4) PMN 
Market 
INSULIN PUMP READY FOR MARKET 
5.4 Determine Secondary Tasks 
The Secondary Tasks were then dctennined and included in Table 6. Unlike the 
Primar y Tasks, addition al Secondary Tasks were added to Column 5.4 to accommodate 
the many com ponents of the insulin pump as wel l as the co mplexity and uniqueness in 
the product and process development of the insulin pump . Like the Primar y Tasks , the 
Seco ndary Tasks were also given unique labels for ease of future ident ificatio n. 
5.5 Estimate Duration of Tasks 
Followi ng the BOPP methodo logy, the estimated durations of Seconda ry Task s 
and Primary Task s without any Secon dary Tasks were noted in Table 6. Due to time 
limitation s, it was not possible to obtain historical data or expert opinions, from people 
who perfom1 these tasks. Therefore, the task durations were estimat ed by the project 
plarmer for the purp ose of this project. The estimated longest (X), most frequent (Y), and 
shortest (Z) possible durations for each of these tasks (in weeks) are prese nted in Column 
5.5 in Tab le 6. 
5.6 Determine Precedences between Primary Tasks 
The precedences between the Primary Tasks were then detell1lined, as shown in 
Column 5.6 in Table 6. Since the list of Primary Tasks was simi lar to the Primary Task s 
in the ge neral flowch art, the precedences were also similar. For exam ple, for Primary 
Task, "Detell1line and Test Sterili zation Method (Sterilization)" , the predecessor is 
Primary Task, "Detenn ine Production Asse mbly Proc ess (Prod)." The Primary Task , 
"Detell1line and Test Sterilization Method (Steri lization)" is also the predecessor for three 
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subsequent Prim ary Ta sks, "Determine Biocompatibilit y (Bio compatibilit y)", " Identif y 
Storage Criteria (Storage)", and "Detem1ine Packaging Material (Packaging)" that are 
perfonn ed simultaneou sly. Th e general precedences between Primar y Tasks were 
confirm ed throu gh interviews and internet corr espondence w ith experts on the subject o f 
insulin pump pro cess developm ent and manufa cturin g. 
5.7 Determine Precedences between Secondary Tasks 
Due to the addition of Secondar y Tasks to accomm odate the insulin pump product 
and pro cess de velopm ent plannin g, addi tional precedences between the Secondar y Tasks 
had to be determined. The method for determinin g the precedences between the 
Seco ndary Ta sks was simil ar to the one used to determine the Primar y Tasks. The 
precedences betwee n the Seco ndary Tasks arc entered in Column 5.7 in Table 6. For 
exampl e, in order for Secondar y Ta sk, "Test So lenoid Motor (MFG _ l0) " to take place, 
the Sec ond ary Task , "As sembl e Solenoid Mot or (MF G _9)" mu st be compl eted first. 
5.8 Identify Potential Repeat Tasks 
Pot ential Repeat Tas ks we re identifi ed while deve lopin g the flowchart for the 
insulin pump produ ct and proces s deve lopment, and are shown in the nowchart in Figure 
40. 
5.9 Develop Flowchart and Create Phantom Repeat Tasks 
The insulin pump deve lopm ent and manufac turin g was depicted in the form of a 
flowc hart (Fi gure 40) . Simil ar to the genera l biomedi ca l dev ice produ ct and process 
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Figure 40: Insulin Pump Product and Process Development Flowchart. 
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Figure 40: Insulin Pump Product and Process Development Flowchart (Cont.). 
development flowchart, the insulin pump product and process development is also 
comprised of three major phases: Product Development or Research and Development 
(RD), Process Development or Manufacturing (MFG), and Regulatory (R_EG). The RD 
phase involves the research and develop ment of raw materials and their preparation for 
manufacturing. The MFG phase is the actual manufacturing of the external insulin pump. 
The REG phase involves the handling of documents for the regu latory approval 
processes. 
In this model, it was assumed that the RD stage begins after confinnation of an 
insulin pump design. The general biomedical device flowchart was the basis of this 
model. The project planner had lo accommodate the speci fie components of the insu lin 
pump within the flowchart. In the insulin pump RD phase, the components of the insuli n 
pump are first detennined (RD_ 1 ). Once this has been done, the raw materials for each 
of the components are researched and documented (RD_2 to RD_l0). The raw materials 
are then tested to ensure their suitability for the insulin pump (RD_ l2 to RD_20). This 
process is iterated until suitable raw materials for each compo nent are found. Al the 
same time, the software code for the insulin pump "microcompute r" is developed and 
tested (RD_ I l and RD_ 21 ). This process is also iterated until the software code is 
deemed satisfactory. Once the raw materials and the software codes are confim1ed, the 
production assembly process is detem1ined (RD_22). At this point, the MFG phase 
commences and flows concurrently with the RD phase in order to speed up design-to-
market time. The RD phase is then continued with the detem1ination of steri lization 
options (RD_ 23). The effects of different sterilization methods are then analyzed 
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(RD_24), and one selected. As shown in the flowchart , the process of finding the 
appropriate steri lization methods is also an iterativ e one. 
After a steril izatio n method is determined , the method is analy zed for particulat e 
contam inants (RD_25). If the level of particulate contami nants exceeds the level allowed 
by the FDA , a new sterilization method is determined. Otherw ise, biocompatibility tests 
(RD_26), identification of storage criteria (RD_27) , and identification of packaging 
materials (RD_28) are then perfom1ed concurrently. After biocompatibility tests are run, 
failure-mode-effect ana lysis is perfom1ed (RD_ 29). If discouragin g results are produced 
by this ana lysis, the requirements for the insulin pump coniponents need to be reanal yzed 
(RD_ I). The packaging mat erials arc also evaluated, and if found unsuitable, the 
identification of appropriate packaging materials is perfonned again. 
The MFG phase is initialized with the construction of a preliminary Good 
Manufacturing Practice (GMP) manufacturing facility (MFG_ !). Then, alternate vendors 
are identified and qualified to assure the highest quality of raw material is acquired 
(MFG_ 2). After that, new and more sophisticated equipm ent is added into this facility 
(MFG_3). A formal production process is then established (MFG_ 4). The batch size and 
frequency of manufacturing is determined (MFG_S). Each step of the production proce ss 
is discussed with the research team to verify the process (MFG_6). Jfa problem is found 
within the proposed production process, an effort is made to revise the production process 
until it can be finalized and implemented. Otherwise, new techniques and equipment for 
scale-up manufacturing are proposed (MFG_ 7). All of the insulin pump components are 
then manufactured in batches (MFG_8). Next, the soleno id motor is assembled (MFG_9) 
and tested (MFG _ I0). This process is iterated until a high quality motor is manufactur ed . 
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The electron ics board or microcomp uter is then assembled (MFG_ I I) and tested 
(MFG_ 12). This is also an iterative process. The so lenoid motor and elect ronics board 
are then assembled on the pump case (MFG _ 13) and tested (MFG_ l4). Then, all the 
components are assembled to fonn the final product (MFG_ l5) and tested (MFG_ 16). 
Once the final product passes all tests, the insulin pump processing events are validated 
to ensure consistent processing (MFG_ l 7). Then, environmental controls are ensured to 
follow federal and state governme nt regulations (MFG_ l 8). 
At this point, the REG process is begun. An Investigation Approval (IA) is filed 
and submitted to an Institut ional Review Board or !RB (REG_ I). This document is 
revised until it is approved by the !RB . Then, follow ing approval, an lnvestigational 
Device Exemption (!DE) is subm itted to the FDA (REG _2). This document is also 
rev ised until approved by the FDA. Clinical testing is then perfom1ed (MFG_19) and a 
Premark et Notificat ion (PMN) is subm itted to the FDA (REG_3). If not approved by the 
FDA , depending on the reasons given, the proce ss could be repeated at Product 
Deve lopment (ReRD) , Process Development (ReMFG), or at clinical testing 
(ReMFG _ l9), as depicted in the flowchart. For example , if probl ems are detem1ined by 
the FDA to be in the Product Development phase (ReRD) , there are probabilities that the 
problem s are caused by the raw materials (ReRaw) , the produ ction assembly proce ss 
(ReProd), the sterilization method (ReSterilization) , or biocompat ibility issues 
(ReBiocompatib ility). 
If problems are detem1ined by the FDA to be in the Process Development phase 
(ReMFG), there are probabiliti es that the probl ems are within the production process 
(ReProdProcess), actua l manufacturing (ReManufactur e), or enviro nmental controls 
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(ReEnvironment). After correcting the problems, the PMN is then resubmitted to the 
FDA. Upon final approval by the FDA, the insulin pump is ready lO be manufactured in 
full-scale for the mass market (PREPMARKET). 
As suggested in the BOPP methodology, eac h task is given a number to facilitate 
coordinat ion with the simulation model that will be developed. 
5.10 Estimate Probabilities of Potential Repeat Tasks and Phantom Repeat Tasks 
The probabilities of potential Repeat Tasks and Phantom Repeat Tasks before and 
after PMN was submitt ed to the FDA, are then detennined. In this example, little data 
was available concerning Repeat Tasks, while in an actual industry application, more 
infonnation would be available. Therefore, due to the lack of actual historical data, these 
probabilities were estimated by the project planner. These probabilities are shown 
directly on the simulation network model. 
5.11 Develop Simulation Network Model 
Using the infonnation galheredin Steps 5.1 to 5.10, the simulation network model 
was developed using the various subnetworks suggested in the methodology. Again, the 
general biomedical device simu lation network model provided the basis for the insulin 
pump model. The project planner had to include additional subnetworks to accommodate 
all the insulin pump components. An overview of the insulin pump simulation network is 
shown in Figure 41. Figure 42 shows an exploded version of the simulation network 
model. The project planner created this model using the stude nt version of the AweSim 
3.0 software, wh ich only allowed the planner to use a maximum of 300 nodes and 
activities. Therefore, due to this constraint, the project planner had to make decisions on 
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Figure 42: Simulation Network Model for Insulin Pump Product and Process Development - Exploded (Cont.). 
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Figur e 42: Simulation Network Model for In su lin Pump Product and Proc ess Development - Exploded (Cont.). 
the locat ions of COLCT nodes for the Repeat Tasks. In the general biomedica l device 
simulation network, COLCT were placed between "SplitS" and "ReM FG_ l 1 ", 
"TypeRD" and " ReProd", "Type RD" and "ReSterilization", "Type RD" and 
"ReBiocompatib ility", "TypeMFG" and "ReManufa cture", "TypeMFG" and 
"ReEnvironment", as well as "TypeMFG" and "ReProdProcess" Due to the node and 
activity symbol limitation s, for the insulin pump simulation netwo rk, COLC T nodes were 
only placed between "T ypeRD" and "ReRaw", "Type RD" and "ReP rod", and 
"TypeMFG" and "Re Manufa cture". These locations were chosen arbitrarily to satisfy the 
300 nodes and activities constraint. 
5.12 Develop Simulation Co ntrol Statements 
The developed simulatio n control statements for the insulin pump example are 
shown in Figure 43. In the GEN statement, the model was first simulated for 20 runs. 
After ana lyzing the results (Section 5. 14), the numb er of runs was increased to 80 to 
obtain more accurate results. 
GEN," Dorene Seah", "lnsulin Pump Product and Process Deve lopment", 7/18/00, 20, 
YES,YES; 
LlMlT S, 11,,,3; 
lNTLC,{ {XX[I ],0. 1 J,{XX[2],0.3),{XX[3],0.4},{XX[ 4],0.2},{XX[5],0.2},{XX[6],0.3 }, 




Figur e 43: Simulation Con trol Sta teme nts of Insulin Pump Product and Pro cess 
Deve lopm ent. 
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In the LIMITS statement, the maximum number of global variables, XX[] was 
11 and the maximum number of attributes, ATRIB[] was 3. 
In the INTLC statement, the variab les, XX[!], XX[2) , XX[ J], and XX[4] 
repres ented init ial probabil ities of 0.1, 0.3 , 0.4 , and 0.2 of loopin g back in the simulation 
model from the submission of PMN (REG _3) to the clinica l test ing (ReMFG_ I 9) task, 
the Manufacturing pha se (ReMFG) and the Researc h and Deve lopment phase (ReRD) , 
respectively. The variabl es, XX[5], XX[6], XX[7], and XX[8] represe nted the 
characteristics of an entity that was looped back to the "ReRD" phase (AT RIB[I] ==2) 
and variables XX[9], XX[ I OJ, and XX[ I I] represented the characteristics of an entity that 
was loop ed back to the 'ReMFG" pha se (ATRIB[ I]==3). Therefore , the variabl es, 
XX[5], XX[6], XX[7 ], and XX[S], repr esented the init ial probabiliti es of 0.2, 0.3, 0 I, 
and 0.2 of another loop back from the submiss ion of PMN (REG_3) to the detennination 
of raw materials (ReRaw) , the determ ination of produ ct assembly proces s (Re Prod), 
detem1ination of ste rilization method and detennination of biocompat ibility. The 
var iable s, XX [9) , XX[l0], and XX[ l I) represe nted the initial probabiliti es of 0. 1, 0.6, 
and 0.3 of anot her loop back from the submi ss ion of PMN (REG_ 3) to the manu facturing 
and asse mblin g of biomedical device components (ReManufacture), detem1ination of 
environmental controls (ReEnvironment), and determination of formal production 
process (ReProdProces s ). 
In the TNIT!A LIZE stateme nt, each run was set to be simulated for 800 weeks . 
As mention ed in the BOPP methodolog y, the N ETWORK and FIN statemen ts were left 
to their default values. 
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5.13 Run S imulati on Mode l 
Afier the development of the s imulati on network mode l and the assoc iated control 
statements , the model was s imulat ed. 
5. 14 Analyze Result s 
As shown in Figure 44, when the mode l was simulat ed for 20 runs of 80 weeks 
each, the resu lts indicat ed that the insu lin pump would be ready for mark et w ith in a mean 
time of 256.4 weeks. The standard deviat ion was 58.J weeks. Ther efore, the half-width 
of the 95% confidence interval was: 
I, = I _ s_ 
0 n0- l ,1-a l 2 .r,;: 
= 2.09 (58.3) 
✓20 
= 27.3 
The half-width represents some I 0.64% error in the point estimate of 256.4. 
Reducing thi s error would make the results more accurate. For examp le, the project 
planner dec ided to reduce this error by half. Therefore, using the formu la suggested in 
the methodology to determine the number of runs needed to reduce to a known half-
width,/, of 13.6: 
"'20 (27.3) ' 
(13.6) ' 
"'80 runs 
Therefore, the model was then simu lated for 80 runs. The results for the 80'h run 
are shown in Figure 45. Compared to the origina l error of I 0.64%, the error has been 
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reduced to 5 .32% with in the point esti mate of274. l . The ou tput echo and interm ed iate 
reports for the simulat ion are shown in Appendices A and B. 
** AweSi m SUMl\'lARY REPORT ** 
Sun Mar 18 21:55 :05 2001 
Simulati on Project : In sulin Pump Product and Proc ess Developme nt 
Modele r: Doren e Seah 
Dat e : 7/18/ 00 
Scenario : BASE CASE 
Run number 20 of 20 
Current simulati on time : 274 .337955 
Stati stics cleared at time: 0.000000 
** OBSERVED STATISTICS REPORT for scenario BASECASE ** 




Va lue Deviation 
Obs. 
Value Va lue 
Determine Insulin Pump 
5.01 I 0.401 23 4. 199 5.861 
Compo nents 
Research and Specify Raw 
9.525 0.809 27 7.964 11.301 
Mater ials for So lenoid Motor 
Research and Specify Raw 
7.992 1.062 28 6.843 10.489 
Materials for Syr inge 
Research and Specify Raw 
9.380 0.805 29 8.43 I 1.017 
Materials for Pump Case 
Research and Specify Raw 
8.483 0.849 26 7.254 9.889 
Materials for Window Panel 
Research and Specify Raw 
Materials for Mechanical I 1.037 0.910 26 9.670 12.641 
Driver Arm 
Research and Specify Raw 
9.239 1.390 25 6.948 12.908 
Materials for Lead Screw 
Research and Spec ify Raw 
Materials for Reservoir 10.321 1.300 25 7. 198 12.410 
Converter 
Research and Specify Raw 
9.745 1.922 28 6.796 13.691 
Materials for Luer Neck Leve r 
Research and Spec ify Raw 
Materials for Battery 8.717 0.553 28 7.486 9.761 
Comoartment 
Develop Code for Software 13.050 0.729 24 12.045 14.3 13 
Test for Suitability of Raw 
14.264 0 .87 1 27 12.372 16. 106 Material s for Solenoid Motor 




1\Jlin. Max . Mean of Lab el Dev iation Va lu e Value Va lu e Obs. 
Test for Suitability of Raw 11.647 1.317 28 9.759 15.133 
Materials for Syri nge 
Test for Suitability of Raw 
13.024 1.080 29 11.503 15.347 
Mate rials for Pump Case 
Tesl for Suitab ility of Raw 
13.9 16 1.43 I 26 11.339 15.753 
Materials for Window Pan el 
Test for Su itability of Raw 
Materials for Mechanica l 15.229 1.949 26 12.233 19.583 
Driver Arm 
Test for Su itab ility of Raw 
13.806 1.625 25 11.559 I 7.7 14 Mater ials for Lead Screw 
Test for Suitab ility of Raw 
Mate rials for Reservoir 15.583 1.915 25 11.773 19.295 
Converter 
Te st for Suitab ility of Raw 
12.741 1.851 28 9.609 16.753 Ma1crial s for Luer Nec k Lever 
Test for Suitab ility of Raw 
Materials for Battery 14.625 1.147 28 12.96 2 16.259 
Co mpartment 
Test Software Code 16.496 I.I 19 24 14.798 18.98 
Detennine Production 
29. 113 5.425 27 22.456 41.624 
Assembly Process 
Determine Steri lization Method 36.498 5.627 44 29.226 49.292 
Analyze Effects of Steril iza tion 40.863 5.51 44 33.995 52.703 
Analyze Particulate 
45.810 5.906 40 37.625 59.064 
Contaminants 
Run Tests to Invest igate 
58.632 14.945 27 40.539 81.36 1 
I3iocompatibility 
Perform Failur e- Mode-Effect-
63.268 14.821 27 44.878 86.388 
Analysis 
Ident ify Storage Cr iteria 56.477 14.866 26 39.496 79.493 
Identify Packaging Material 55.715 14.749 29 40.258 79.880 
Evaluate Packaging Material 57.676 14.772 29 42.148 81.523 
Co nstruct Preliminar y GM P 
42.153 5.336 26 36.056 54.674 Manufacturing Fac ility 
Figure 44 : Results of 20 th Simulation Run - Observed Statistics Report (Cont.). 
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St a nd a rd 
No. 
M in . l\1;1x. M ea n of Lab el Dev iati on Value Va lu e Va lu e Obs. 
Identify and Qualify Alternate 47.26 1 5.35 9 
Vendors 
26 4 1.414 59.632 
Install New Equipmen t 51. 16 1 5.45 6 26 44.79 63 .955 
Estab lish Formal Prod uctio n 
88.663 30.46 6 48 5 1.420 157.100 
Process 
Dete rmine Batc h Size an d 
90.963 30.553 4 7 54.415 160.029 
Frequency o f Man ufacturi ng 
Discuss with Rese arch Team 
and Con firm Each Step of 93.969 30.620 47 57.440 163. 150 
Prod uction Pro cess 
Propose New Techni ques and 
Equipmen t for Sca le-U p 100.656 30.236 44 66.086 167.339 
Manufacturi ng 
Man ufacture Insul in Pump 
109.370 30.875 43 75.225 175.75 1 
Compo nents 
Asse mble So lenoid Moto r 116. 166 3 1.220 53 81.070 180 .803 
Test So leno id Motor 12 1.113 3 1.602 52 86.261 186.5 13 
Assemb le Electro nics Boa rd 124 .193 29.083 66 90.059 190.73 4 
Tes t Electronics Board 130 .166 28.936 66 96.257 195.550 
Assemb le So lenoi d Mot or and 
Electronics Board on Pump 143.810 3 1.96 1 54 101.658 212.444 
Case 
Test Solenoi d Motor an d 
Elec tron ics Board on Pum p 146 .3 16 32.233 53 103.843 2 15.225 
Case 
Asse mble Final Product 153.070 29.695 45 109.432 217.93 1 
Test Final Product 156.6 14 29.985 45 112.66 1 222.098 
Va lida te Insu lin Pump 
I 66.589 30.442 32 119.334 226.996 Processing Eve nts 
Ensure Env ironmental Co n1rols 
167 .944 32.3 16 38 123.549 231.327 Follow Regulations 
File For Investigat iona l 
178.206 3 1.980 35 128.847 236.423 Appro val by !RB 
Figure 44 : Results of 20th Simul ation Run - Obse rved Statistics Report (Co nt.). 
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Stirnd a rd 
No. 
Min . M a x. M ean of Lab el V:ilue Deviation V:ilu e Value 
Ob s. 
Submit Invcstigational Devi ce 
184.625 32.497 37 138 .779 247463 
Exemption to FDA 
Perform Clinical Testing 197.754 30.400 32 149.600 259.653 
Submit Premarket Notification 
195.805 27.3 49 45 I 54.087 263.65 9 
SIOK 
Prepare Insulin Pump for 
256.364 58.335 20 180.18 3 386.383 
Marke t 
Insulin Pump Ready for 
256.364 58.335 20 180.183 386.383 
Market 
ReRawFrReRD 253.336 89.8 12 2 I 89.829 316.842 
ReProdFrReRD 265.236 37.383 2 238.802 291.670 
RcManufactureFrReMFG I 98.608 0.000 I 198.608 198.608 
Figure 44: Results of 20th Simulation Run - Observed Statistics Report (Cont.) . 
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** AwcSim SUMMARY REPORT ** 
Sun Mar 18 21 :55:05 200 1 
Simulation Project : Insulin Pump Product and Proce ss Develo1un ent 
Modeler : Doren e Seah 
Date : 7/18 /00 
Scenario : BASE CAS E 
Run number 20 of 20 
Current simulation time : 274.337955 
Statistics cleared at tim e : 0.000000 




Label of Value Deviation 
Obs . 
Value Va lue 
Determin e Insulin Pump 
5.004 0.380 112 4.199 5.931 
Component s 
Researc h and Speci fy Raw 
9.4 79 0.856 126 6.7 19 11.351 
Material s for So lenoid Motor 
Research and Specify Raw 
8.273 0.940 127 5.946 11.014 
Materials for Syr inge 
Resea rch and Speci fy Raw 
9.6 19 0.736 124 8.240 11.205 
Mate rials for Pump Case 
Researc h and Specify Ra w 
8.388 0.697 130 6.5 89 9.92 1 
Material s for Wind ow Panel 
Researc h and Specify Raw 
Materials for Mechanica l 11.080 0.861 130 9.2 33 13.158 
Driver Arm 
Researc h and Specify Raw 
9.335 1.8 18 122 6. 154 13.496 
Materials for Lead Screw 
Research and Spec ify Ra w 
Material s for Rese rvoir 10. 162 1.075 122 7. 198 12.410 
Converter 
Research and Spec ify Raw 
9.6 8 1 1.840 125 6.174 14.107 
Materia ls for Luer Nec k Leve r 
Resea rch and Speci fy Raw 
Materials for Battery 8.759 0.638 125 7.24 1 10.5 13 
Compartment 
Develop Code for Software 13.054 0.688 122 12.045 14.42 1 
Test for Suitabilit y of Raw 
13.992 0.976 123 11.110 16.106 Materials for Sole noid Moto r 
Test for Su itab ility of Raw 
11.598 1.179 126 9.280 15. 133 Materials for Syringe 
Test for Suitabi li1y of Raw 
13.379 0.962 120 11.426 15.481 Material s for Pump Case 
Figure 45: Results of 80th Simu lation Run - Observed Statistics Report. 
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Mea n Sta ndar d 
No. 
Mi n . Max . 
Labe l Va lue Deviat ion 
of 
Va lue Va lue 
Obs. 
Test for Suit abilit y of Raw 
13.333 1.352 128 10.705 16.289 
Materials for Window Panel 
Test for Suitability of Raw 
Mate rials for Mechanical 15.045 1.855 127 11.592 19.583 
Driver Arm 
Test for Suitabi lity of Raw 
14.064 1.962 119 10.849 18.188 
Material s for Lead Screw 
Test for Suitabi lity of Raw 
Material s for Reservo ir 15.297 1.669 117 11.63 19.295 
Conve rter 
Test for Sui tabilit y of Raw 
12.710 1.792 123 8.819 16.978 Materials for Luer Neck Lever 
Test for Su itab ility of Raw 
Material s for Battery 14.866 1.402 121 11.600 17.435 
Compar tment 
Test Software Code 16.526 0.923 I 18 14.713 18.980 
Deter mine Product ion 
29.634 4.481 262 2 1.169 45.042 
Assembly Process 
Determ ine Sterilization Method 36.486 4.708 414 26.856 51.638 
Ana lyze Effects of Sterilization 40.802 5. 126 382 3 1.420 56.986 
Analyze Particulate 
45.499 5.619 295 35.124 63.465 
Contami nants 
Run Tests to Investigate 
68.556 19.865 174 39 .675 112.303 
Biocompatibility 
Perfor m Failure -Mode -Effect-
73.489 20.215 168 42 . 138 I 19.604 
Ana lysis 
Identify Storage Criteria 66. 587 19.648 165 36.963 109.7 15 
Identify Packag ing Material 67 .249 20.231 204 37.203 I 10.639 
Eva luate Packaging Mate rial 68. 799 19.866 201 39. 109 112.403 
Construct Preliminary GMP 
43.065 4 .698 192 34.499 59.2 14 Manufa ctur ing Facili ty 
Identify and Qualif y Alternate 
47.984 4.860 181 39. 188 64 .340 Vendors 




Min. Max. Mean of Label Deviation Value Value Value Obs. 
Install New Equipment 52.025 4.901 180 42.95 5 69. 189 
Establi sh Formal Production 
85.233 24.818 422 51.420 157.J.00 
Proce ss 
Dete rmine Batch Size and 87.785 24.431 401 54.415 160.029 
Frequenc y of Manufacturing 
Discuss with Research Team 
and Confirm Each Step of 90.96 3 24291 385 57.44 163.150 
Production Process 
Propo se New Techniques and 
Equipment for Sca le-Up 98 .035 25. 150 298 63.442 168.908 
Manufacruring 
Manufacture Insulin Pump 
106.322 26 .5 18 240 72.013 176.378 
Componen ts 
Assemble Solenoid Motor 112.933 28.454 259 77.271 182.328 
Test Solenoid Motor 117.596 29.386 240 80.213 186.513 
Assemble Electronics Board 121.949 28.936 278 84.785 197.598 
Tes t Electronics Board 127.696 28.785 273 90.732 202 .952 
Assemble Solenoid Motor and 
Electron ics Board on Pump 142.723 30. 146 232 95.552 212.444 
Case 
Test So lenoid Motor and 
Electronics Board on Pump 146.126 30 .343 226 99 .689 215.225 
Case 
Assemble Final Product 152. 193 29.652 195 102.24 1 217.931 
Test Final Product 156.05 7 29.829 191 106.243 222.098 
Va lidate Insulin Pump 
165.767 32.23 9 112 111.810 231.0 15 
Processing Events 
Ensure Environmental Controls 
168.010 32.5 19 132 116.704 236.636 
Follow Regulat ions 
File For lnvestigational 
178. 18 1 33.447 120 122.015 242.764 Approval by !RB 
Submit lnvestigationa l Device 
186.699 33.4 41 134 132.696 251.446 Exemption to FDA 




M in. Max. Mean of Label Va lue Deviation Va lue V:llu e 
O bs. 
Perfonn Clinical Tes ting 199.332 3 1.07 1 116 144.052 27 1.071 
Submit Premarket Notifi cation 
198.392 27.525 196 148.001 275.70 0 
5 10K 
Prepare Insulin Pump for 
274. 100 61.806 80 I 60.024 405.375 
Market 
Insulin Pump Rea dy for 
274.100 61.806 80 160.024 405.375 
Market 
RcRawfrReRD 224.359 48.994 7 170.891 316.842 
ReProdFrReRD 248.33 8 38.206 8 195.635 291.6 70 
ReManufactureFrReMFG 191.064 10.669 2 I 83.52 0 198.608 
Figure 45: Results of 80 th Simulation Run - Observe d Statistics Report (Cont.). 
Figure 45 shows that the mean completion time for the insulin pump projec t was 
est imated at 274. 1 weeks. The shorte st possible compl etion time of product and process 
development of the insulin pump was an estimated 160.0 weeks. The longes t possib le 
comp lelion time was estimat ed at 405.4 weeks. The standard dev iation was 6 1.8 weeks. 
Therefore , the standard erro r of the mean project completio n times is approximately 6.9 
weeks. Assum ing a nonn al distribution, a 95% confide nce interval for the mean project 
complet ion is approximate ly two standard errors from the mean (Pritsker et al. , 1994). 
Therefore , it can be estim ated that there is a probabi lity of 0.95 that the true mean of the 
proj ect's compl etion time lies betwee n 260.3 and 287.9 weeks. 
A histogram report of the results is shown in Figure 46. By analy zing the 
histogram report (Figu re 46), it is pos sible to estimate the probabilit y of the project being 
co mpleted in a spec ified duratio n. For exampl e, by lookin g at the 13'" ce ll of the 
histogram report, it can be see n that there were 6 case s, or observed rnns, where the 
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insulin pump product and process deve lopment com plet ion time were greater than 2 10 
weeks but less than or equal to 220 weeks. 
Observed Relativ e Frequenc y 
Cumu lative 
Upper Cell Limit 
Fr eo uencv Frequency 
0 0.000 0.000 100 
0 0.000 0.000 I 10 
0.000 0.000 120 
0.000 0.000 130 
0 0.000 0.000 140 
0 0.000 0.000 150 
0 0.000 0.000 160 
I 0.013 0.013 170 
0 0.000 0.0 13 180 
0.037 0.050 190 
0.037 0.087 200 
9 0.113 0.200 210 
6 O.Q75 0.275 220 
0.063 0.338 230 
0.037 0.375 240 
0.037 0.4 12 250 
0.037 0.45 260 
0.037 0.487 270 
0.037 0.525 280 
O.Q75 0.600 290 
0.050 0.650 300 
0.063 0.7 13 310 
0.037 0.750 320 
0.037 0.787 330 
0.037 0.825 340 
0.063 0.887 350 
0.037 0.925 360 
0.000 0.925 370 
0.000 0.925 380 
0.037 0.963 390 
0.013 0.975 400 
O.Q25 1.000 410 
0 0.000 1.000 420 
0 0.000 1.000 430 
0 0.000 1.000 440 
0 0.000 1.000 450 
0 0.000 1.000 460 
0 0.000 1.000 470 
0 0.000 1.000 480 
0.000 1.000 490 
0 0.000 1.000 500 
0 0.000 1.000 IN FINITY 
Figure 46 : Observed Statistics Histogra m Report for 80th Run . 
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The relative frequenc y o f this observation is 7.5% .The cumulative frequency associated 
with 220 weeks is 0.28 . Th ere fore, it can be es tim ated that the probability of the projec t 
being comp leted withi n 220 weeks is 0.28. The estimated probabili ty of the project 
takin g longer than 220 weeks is 0. 72. A graphical version of the histog ram repo rt is 
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Fig ure 47: Cumul at ive Freq uency of Project Comp letion T imes for 80 Run s. 
These simulation results also provide a strong basis for pred icting two of the main 
perfom1ance measures of projec t planning: the projec t comp letion time and the risks 
invo lved w ith the project. Based on these res ults , biomanufacturing compan ies are able 
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to make product and process decisions. By doing so, they arc also able to make better 
investment decisions. 
Based on the estimated duration of the entire biomedical device product and 
process development provided by the results of the simul ation, project planners may 
choose to add or delete tasks deemed necessary for the proje ct and to reduce or add more 
time to the proj ect. The project planner ma y also choose to review the precedences or 
activities in order to shorten the project completion time. Th e results of the simulation 
provide supporting documents to justify these actions to upper management. 
These results also show the risks of completing a certain project later than the 
schedu led market date. Ir the simulation shows high prob abi lity that a certain biomedical 
device project plan wi ll not meet its scheduled date, upp er management may choose to 
change the timeline and propose a more reasible date for marketing the product, instead 
of striving to meet an impossible schedule. This wil l satisfy two important criteria withi n 
the manufacturing indu stry, that is, to deliver products that are high quality and on the 
date that they were promised (on-time deliveries). 
148 
C HAPTER 6 
CONCLUS IONS AND RECOMMENDAT IO NS 
This chapter provides the summary and conclusions of this research as we ll as 
recommendations for future research. 
6.1 Summar y 
Th e rapidly changing biomedical device industry and the associated pace of the 
advancement of technology requires that biomedical dev ice compan ies release products 
into the marketp lace as fast as poss ible to recoup the investment made into them as wel l 
as to deal with fierce competition. The product and process development of biomedical 
devices differ greatly from other products due to the uniqu eness of bioma nufacturing. 
Th e field of biomanufacturing is uniqu e in terms of the integration of adva nced 
techno logies, the inte gra tion of biomedical devices with the human body, governme nt 
regu lation s, biomedical product liabi lity issues, soc ial and ethica l issues, and steri lizat ion 
method s. Although well-planned product and process development can ens ure rapid tim e 
to market , fast product ion ramp-up, and more solid propr ietary position for 
biomanufacturers, most biomedica l device manufacturers have the tendency to 
concentrate on improvin g product development issues rather than accelerating their 
process deve lopment. 
There are many methods recommended to acce lerate product development. Th ey 
include imp lementatio n of support systems and techniques, speeding up activ ities or 
tasks, reduction of parts or components in products, supplier involvement, simplif ying 
opera tion s, eliminating delays, eliminating steps, and processing steps in parallel. These 
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melhods can be incorporaled into a simulati on network model during the project planning 
stage to estimate their effectiveness, while taking the uniqueness of biomanufacturing 
under consideration. 
The methodolo gy for deve loping the general biom edica l device produc t and 
proce ss deve lopment simulation model consists of 14 steps from the development of the 
model to the analysis of the results. For ease of use, a template for this simulation model 
has been provid ed. A project plann er will be able to save time by modif ying the template 
to meet the needs of a speci fie biom edical device. Otherwise, a unique biomedical device 
product and proc ess developm ent simulation network model can be deve loped by 
following the instructions in the methodo logy. 
6.2 Concl usions 
Th e objective of deve lopin g a simulation too l using the SLAM I! language to 
facilitate proj ect mana gement in biom edical device product and proce ss deve lopment was 
accomplished. Throu gh extensive research , taking the uniqu eness of biomanufa cturing 
into consi deration , a methodolo gy was developed that addresses the needs of biom edical 
device com pani es in impro ving the plannin g related to the development of their products 
and associated production processes. Thi s research concentrated on the creation of a 
simulation tool that considers produ ct and process deve lopment failures and the 
recngineering of those activi ties, the impact of government regulations and the approval 
process, along with their impact on produ ct and process development, as we ll as multiple 
subproc ess failures with time var iant probabiliti es. This was achieved through the 
deve lopment of a methodology to aid the project plann er in deve loping and using a 
simulation network model for biomedical device product and process development. Thi s 
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research also provided an examp le app lication of the methodo logy depicting the product 
and process development ofan external insulin pump . 
6.3 Reco mmendations for Futur e Research 
Besides proj ect comp letio n time and the assoc iated risks of the project be ing 
completed withi n a certain duration, another key measure in project management and 
planning is project costs. Th erefor e, for future researc h, it would be beneficia l to expand 
the simulat ion model to includ e proj ect costs. The SLAM 11 language can be used to 
incorporate this performanc e measure into a simulation model. 
Due to the limitation s of time and infonnation ava ilability, the durat ions of all 
tasks and prob abilities of Repeat Tasks were est imated by the project planner. In actual 
industry application, these durations and prob abili ties shou ld be consta ntly validated, 
monitored, and updat ed durin g and after the actual project. The durations can be 
obtained throu gh discussions with the personnel who have exper ience in performin g the 
tasks and plannin g documents such as work center repo rts that include standard labor run 
rates. These durat ions can be va lidated by comparing the estimated dura tions with the 
durations in actual labor report s. Project completion time can also be validated by 
compar ing the simulation estimated time that the biomedical device will be ready for 
market with the actual time the biom edical device is ready for market. These data wi ll be 
helpful in future creation of more accurate project planning rrlodels. 
The biomedica l dev ice project plannin g model that was crea ted within this thesis 
concentrated on product and process development tasks. O n a broader perspective, the 
BOPP methodo logy can also be used to incorporate other groups within an organizat ion, 
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such as marketing and finance , in the development process. This may result in a more 
accurate planning as all the departments are involved in the planning process. 
It is also recommended that researc h is made to invest igate the linking of popular 
project planning software such as Microsoft Project wit h SLAM 11, in order to increase 
usability. Most proj ect planning softwa re in the market do not have the capability of 
estimatin g risks or probabilities of project failure. The integra tion of these software and 
the simulation in the BOPP methodology wi ll greatly benefit project planners. 
It would also be helpful if an object-oriented interface is created for the proj ect 
planner to ente r the information needed to develop the flowchart and simulation model. 
This interface should include Primary and Secondary task name s, durations, and 
precedence s. Not only will this ease understanding of the required input s, it will also 
make it eas ier to track data inputs. If the interface is linked to a database, it w ill also 
enable the project planner to track historical data, as the databas e can be updated for 
accuracy dur ing the project itself. 
It is also possible to build a model generator, which will automat ically create the 
simulation mode l, based on data in the templates. This addition would great ly enhance 
the usabilit y of the BOPP methodology and make it availab le to a wider audience. The 
user interface could also be enhanced to run the models automatically, and col lect and 
display data in forms that support the project pl aimer . 
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APPENDIX A 
OUTPUT ECHO REPORT 
159 
Awesim Input Translator, version 3. O 
Copyright (CJ 1999 symix Systems, Inc . 
Reading control BIOMll 
1 GEN, "Dorene Seah", "Insulin Pump Product and Process 
Development", 7/18/00, 80, YES, YES; 
2 LIMITS,11,, ,3; 
3 
INTLC, { { XX [ s I , o . 2 ) , { XX [ 6 I , o . 3 ) , { XX I 7 I , 0 . 1) , { XX [ 8 I , o . 4 ) , { XX I 9 I , o. 1 ) , { XX I 
10] ,0.6), {XX[ll] ,0.3), {XX[l] ,0.1), {XX[2] ,0.3 ) , {XX[3] ,0.4 ), {XX[4] ,0 2)}; 
4 INITIALIZE, 0. 0, 800, NO, , YES; 
5 NETWORK, READ; 
6 FIN; 
BIOMll successfully read 
Translated file BASECASE successfully written 
Reading network INSl - Pass 1. 
INSl - Pass 1 successfully read 
Reading network INSl - Pass 2. 
INSl - Pass 2 successfully read 
Reading network INSl - Pass 3. 
1 START: CREATE, 0. 0, 0. 0, , 1, 1; 
2 ACTIVITY; 
3 TypeSTART, ASSIGN, { {ATRIB [l] , 1)), l; 
4 ACTIVITY; 
5 ReComponents: GOON, 1; 
6 ACTIVITY,l,TRIAG(4,5,6); 
7 RD_l: COLCT, 1, FIRSTARRIVE, "Determin e Insulin Pump 
Components", , , , 10; 
8 ACTIVITY; 
9 ACTIVITY,,,, "ReRD_3"; 
10 ACTIVITY, , , , "Re RD_ 4"; 
11 ACTIVITY,,,, "ReRD _5 "; 
12 ACTIVITY,,,, " ReRD_6"; 
13 ACTIVITY,,,, "ReRD_7"; 
14 ACTIVITY,,,, "ReRD_B"; 
15 ACTIVITY,,,, "ReRD 9"; 
16 ACTIVITY,,,, "ReRD=lO"; 
1 7 ACTIVITY, 10 0, , , "Re RD 11" ; 
18 ReRD_2: GOON, l; -
19 ACTIVITY,2,TRIAG(2,5,6); 
20 RD 2: COLCT, 2, FIRSTARRIVE, "Research and Specify Raw Materials for 
solenoid Motor",, , , 1; 
21 ACTIVITY, 12, TRIAG(3, 5, 6); 
22 RD_l2: COLCT,12,FIRSTARRIVE, "Test for Suitability of Raw Materials 
for Solenoid Motor", , , , 1; 
23 ACTIVITY,42, ,PROB(O.l), "ReR D_2 "; 
160 
24 ACTIVITY,32, ,PROB(0.9); 
25 Splitl : GOON,l; 
26 ACTIVITY,, ,ATRIB[l]= =l ; 
27 ACT IVITY,,,ATRIB[ l ] ==3 ,"ReP r-od "; 
28 ACTIVITY ,, ,ATRIB[ l ] ==2 , "Re Pr-od "; 
29 Accuml: ACCUMULATE,10,10,LAST,l; 
3 0 ACTIVITY; 
31 ReProd: GOON,l; 
32 ACTIVITY, 144, TRIAG (5, 7, 8); 
33 RD_ 22: COLCT, 22, F IRSTARRIVE, "Determine Production Assembly 
Process ",,, ,2; 
34 ACTIVITY; 
35 ACTIVITY,53,TRIAG(l2,13,15),, "MFG l"; 
36 ReSterilization: GOON, l; 
37 ACTIVITY,52,TRIAG(5,7,8); 
38 RD_23: COLCT,23,FIRSTARRIVE, "Determine Steriliza tion Method",,, ,l; 
39 ACTIVITY,54,TRIAG(2,5,6}; 
40 RD 24: COLCT,24,FIRSTARRIVE, "Analyze Effects of 
Sterili zat io n",,,, l; 
41 ACTIVITY,58, ,PROB(0.2), "ReSterilization"; 
42 ACTIVITY,57,TRIAG(2,4,6 ) ,PR OB(0.8); 
43 RD_25: COLCT,25,FIRSTARR IVE , "Analyz e Particulate 
Contami nants", , , , 1 ; 
44 ACTIVITY,61, ,PROB{0.4}, "ReSterilization"; 
45 ACTIVITY,60, ,PROB(0 . 6); 
46 Split2 : GOON,3; 
4 7 ACTIVITY; 
48 ACTIVITY,65,TRIAG(l,2,3 ) ,, "RD _27 "; 
49 ACTIVITY,,,, "RePackaging"; 
SO ReBiocompatibility: GOON, l; 
51 ACTIVITY, 60, TRIAG (1, 5, 6); 
52 RD_26: COLCT,26,FIRSTARRIVE, "Run Tests to Investigate 
Biocompatibility",, , , 1; 
53 ACTIVITY,62,TRIAG(2,S,8 ) ; 
54 RD_29: COLCT,27,FIRStARRIVE, " Perform Failure - Mode - Effect 
Analysis " ,,, ,1; 
55 ACTIVITY, 74, ,ATRIB [1] ==2 ; 
56 ACTIVITY,74, ,ATRIB[l] ==3 ; 
57 ACTIVITY,64,,ATRIB[l]==l,"Spl it3 "; 
58 Split4: GOON,l; 
59 ACTIVITY,98, ,PROB(0. 3), "ReComponents"; 
60 ACTIVITY,75, ,PROB(0.3 ) , "RePMN"; 
61 ACTIVITY, 76, , PROB ( 0. 4) , "RePr odProcess "; 
62 Split3: GOON,l; 
63 ACTIVITY, 72, , PROB ( 0. 2) , "ReC ompone nts"; 
64 ACTIVITY, 7 3, , PROB ( 0. 8) ; 
65 Accum2: ACCUMULATE,3,1, LAST,1; 
66 ACTIVITY; 
67 Accum3: ACCUMULATE, 2, 1, LAST, l; 
68 ACTIVITY; 
69 ReProdProcess : GOON, l; 
70 ACTIVITY,78,TR I AG(S,6,7 ); 
71 MFG_4: COLCT, 34 , FIRSTARRIVE, " Establish Formal Production 
Pr-ocess",,,, l; 
72 ACTIVITY,79,TRIAG(l,3,S); 
73 MFG_5 : COLCT, 35, FIRSTARR IVE, "Dete r mine Bat c h Size and Fr- eque n cy of 
Manufacturing",,,, l ; 
16 1 
74 ACTIVITY,80,TRIAG(2,3,4); 
75 ME'G 6 : COLCT,36,E'IRSTARRIVE, "Di scuss with Research Team and 
Confirm Each Step of Production Process", , , , 1; 
76 ACTIVITY, 96, , PROB ( 0. 1) , "ReProdProcess"; 
77 ACTIVITY,82,TRIAG(3,6,10),PROB(0.9); 
78 MFG 7: COLCT,37,E'IRSTARRIVE, "Propose New Techniques and Equipment 
for Scal~-Up Manufacturing",,,, l; 
79 ACTIVITY; 
80 ReManufacture: GOON, 1; 
81 ACTIVITY,83,TRIAG{7,8,12); 
82 MFG_8: COLCT, 38, FIRSTARRIVE, "Manufactur e Insulin Pump 
Components ", , , , 1; 
83 ACTIVITY; 
84 ReMFG_9: GOON, 1; 
85 ACTIVITY, 84, TRIAG ( 2, 7, 9) ; 
86 MFG _9 : COLCT, 3 9, FIRST ARRIVE, "Assemble Solenoid Motor", , , , 1 ; 
87 ACTIVITY,85,TRIAG(l,5,7); 
88 MFG_l0: COLCT,40,FIRSTARRIVE,"Test Solenoid Motor",,,,1; 
89 ACTIVITY, 97,, PROB (0 . 2), " ReMFG 9"; 
90 ACTIVITY,87,,PROB{0.8); -
91 ReMFG_ll : GOON,l; 
92 ACTIVITY,87,TRIAG(2,5,6); 
93 MFG_ll : COLCT, 41, FIRSTARRIVE, "Assemble Electron ics Board",,,, 1; 
94 ACTIVITY,88,TRIAG(4,6,8); 
95 MFG 12: COLCT, 42, FIRST ARRIVE, "Test Electronics Board", , , , 1; 
9 6 ACTIVITY, 91 , , PROB ( o . 3) , " Re MFG 11" ; 
97 ACTIVITY, 90, , PROB ( 0 . 7) ; -
98 ReMFG_13: GOON,1; 
99 ACTIVITY,90,TRIAG(3,6,7); 
100 MFG_l3: COLCT,43,FIRSTARRIVE, "Assemble Solenoid Motor and 
Electronics on Pump Case",,,, 1; 
101 ACTIVITY,92,TRIAG(l,4 , 5); 
102 MFG_l4: COLCT,44,FIRSTARRIVE, "Test Solenoid Motor and Electronics 
on Pump Case",,,, l; 
103 ACTIVITY,95, ,PROB(0.2), "ReMFG 13"; 
104 ACTIVITY,94, , PROB(0.8); -
105 ReMFG 15: GOON,l ; 
106 ACTIVITY, 94, TRIAG (2, 3, 4) ; 
107 MFG 15: COLCT,45,FIRSTARRIVE,"Assemble Final Product",,,,1; 
108 ACTIVITY, 99,TRIAG{2,4,5); 
109 MFG 16: COLCT,46,FIRSTARRIVE,"Test F inal Product",,,,!; 
110 ACTIVITY, 101,, ATRIB [1] ==1; 
111 ACTIVITY,104,,ATRIB[l]==3,"Split6"; 
112 ACTIVITY,104, ,ATR IB[l]==2, "Sp lit6"; 
113 Spl i ts : GOON , 1; 
114 ACTIVITY, 102,, PROB (0 .1), "ReMFG_lS"; 
115 ACTIVITY, 103,, PROB (0 . 9); 
116 ReMFG_17: GOON,l; 
117 ACTIVITY,103,TRIAG(3,6,7); 
118 MFG_l7: COLCT,47, FIRSTARR IVE, "Va lidate Insulin Pump Processing 
Events",,,, l; 
119 ACTIVITY; 
120 ReEnvironment: GOON, 1; 
121 ACTIVITY,109,TRIAG(3,5,6); 
122 MFG_lB: COLCT,48,FIRSTARRIVE, "Ensure Environmental Controls Follow 
Regulations",,,, 1 ; 
123 ACTIVITY,112, ,ATRIB[l]==l; 
162 
12 4 ACTIVITY, 113, ,ATRIB[1]==2, "Sp lit?" ; 
125 ACTIVITY,113, ,ATRIB[l)= :3 , "Split7"; 
126 ReIA : GOON,l; 
127 ACTIVITY,112,TRIAG(4 ,6,7); 
128 REG_l: COLCT,49,FIRSTARRIVE, " File for Investigat iona l Approval by 
IRS ", , , , 1; 
129 ACTIVITY,115,TRIAG(2,3,4); 
130 SplitB: GOON,l; 
131 ACTIVITY, 116,, PROB (0 . 1), "Re IA"; 
132 ACTIVITY, 117,, PROB (0 . 9); 
13 3 ReIDE: GOON,1; 
134 ACTIVITY,117,TRIAG(5,7,8); 
135 REG_2: COLCT, 50, FIRSTARRIVE, "Submit Investigational Device 
Exemption to FDA",,,, l; 
136 ACTIVITY, 118, TRIAG {4, 5, 6); 
137 Split9: GOON,1; 
138 ACTIVITY,120, ,PROB(0.2), "ReIDE"; 
13 9 ACTIVITY, 119, , PROB ( 0 . 8) ; 
140 ReMFG 19: GOON,1; 
141 ACTIViTY,119,TRIAG(S,8,9); 
14 2 MFG_l9: COLCT, 51, FIRST ARRIVE, "Perform Clinical Testing", , , , 1; 
14 3 ACTIVITY; 
144 RePMN: GOON,1; 
145 ACTIVITY, 121, TRIAG (3, 4, 5); 
146 REG_3 : COLCT, 52, FIRSTARRIVE, "Submit Premarket Notification 
510K", ,, ,1; 
147 ACTIVITY, ,TRIAG{B, 9, 10); 
148 SplitlO: GOON,l; 
149 ACTIVITY, 123,, ATRIB [l] ==1; 
150 ACTIVITY, 124, , ATRIB [l] ==3, "TypeMFGl"; 
151 ACTIVITY, 125, , ATRIB [ l] ==2, "TypeRDl"; 
152 Splitll: GOON,l; 
153 ACTIVITY,148,,PROB(XX(l]),"ReMFG 19"; 
154 ACTIVITY,149,,PROB(XX[2]),"ReRD"°7 
155 ACTIVITY, 150,, PROB (XX [3]), "ReMFG"; 
156 ACTIVITY,127,,PROB(XX[4)); 
157 Market: GOON, 1; 
158 ACTIVITY,114,TRIAG(2,3,4); 
159 PREPAREMARKET : COLCT, 53, FIRSTARRIVE, "Prepar e Insulin Pump for 
Market",,,, 1; 
160 ACTIVITY,127; 
161 READYMARKET: COLCT, 54, FIRSTARRIVE, "Insu lin Pump Ready for 
Market'',40,100,10,1; 
162 ACTIVITY; 
163 END: TERMINATE, l; 
164 TypeMFGl: 
ASSIGN, ( (xx [11, o. 1}, (xx [21, o .1}, (xx [31, 0 . 1), (xx [41, o. 7}}, 1; 
165 ACTIVITY; 
166 Split13: GOON,1; 
167 ACTIVITY, 133,, PROB (XX [l]), "ReMFG 19 "; 
168 ACTIVITY, 129,, PROB (XX [4]) , "Market"; 
169 ACTIVITY, 136,, PROB (XX [2]) ; 
170 ACTIV IT Y, 135,, PROB (XX [3)), "TypeMFG3"; 
1 71 TypeRD3: 
ASSIGN, ({ XX[5] ,0.4}, (XX[6] ,0.2}, ( XX[7] ,0.3}, (X X[B] ,0.1} }, 1; 
1 72 ACTIVITY; 
173 ReRD: GOON,l; 
163 
17 4 ACTIVITY; 
175 TypeRD, ASSIGN, { {ATRIB {1], 2}}, 1; 
176 ACTIVITY, 137,, PROB (XX (5]); 
1 77 ACTIVITY, 14 0, , PROB (XX ( 8] ) , "ReBiocompatibili ty"; 
178 ACTIVITY, 13 9, , PROB (XX [7] ) , "ReSteri 1 iza tion"; 
179 ACTIVITY,138, ,PROB(XX[6]), "RepeatProd"; 
180 Repea tRaw: COLCT, 55, FIRSTARRIVE, "ReRawFrReRD", , , , 1; 
181 ACTIVITY; 
182 ReRaw: GOON, l; 
183 ACTIVITY,150, ,PROB(0.l), "ReRD _2" ; 
184 ACTIVITY,159, ,PROB(0.l), "ReRD_ll"; 
185 ACTIVITY,158, ,PROB{0.l), "ReRD 10"; 
186 ACTIVITY, 157,, PROB {0 .1), "ReRD - 9"; 
187 ACTIVITY,156, ,PROB(0.l), "ReRD-8"; 
188 ACTIVITY,155, ,PROB{0.l), "ReRD=7"; 
189 ACTIVITY,154,,PROB{0.l),"ReRD_6"; 
190 ACTIVITY,153,,PROB(0.l),"ReRD_5"; 
191 ACTIVITY,152,,PROB(0 . l),"ReRD_4"; 
192 ACTIVITY,151, ,PROB(0 . l), "ReRD_3"; 
193 Repeat Prod: COLCT, 56, FIRSTARRIVE, "ReProdFrR eRD", , , , 1; 
194 ACTIVITY,,,, "Re Prod"; 
195 TypeMFG3 , ASSIGN, { {xx {9], 0.1), {xx {10], 0.2}, {xx {11], 0. 7}}, l; 
196 ACTIVITY; 
197 ReMFG: GOON, 1; 
198 ACTIVITY; 
199 TypeMFG, ASSIGN,{{ATRIB{ll,3}},1; 
200 ACTIVITY,141,,PROB(XX{9]); 
201 ACTIVITY, 14 3, , PROB (XX (11) ) , "ReProdProcess"; 
202 ACTIVITY, 142, , PROB (XX [10] ) , "ReEnvironment"; 
203 RepeatManufacture: 
COLCT, 57, FIRSTARRIVE, "ReManufactureFrReMFG",,,, l ; 
204 ACTIVITY,,,, "ReManufacture"; 
205 TypeRDl: 
ASSIGN, {{XX{l] ,0.08), {XX{2] ,0.03), {XX{3] ,0.03}, {XX{4] ,0.86}},1; 
206 ACTIVITY; 
207 Splitl2: GOON,l; 
208 ACTIVITY, 14 5, , PROB (XX [l] ) , "ReMFG_19"; 
209 ACTIVITY,128,,PROB(XX[4]),"Market"; 
210 ACTIVITY,146,,PROB(XX[2]); 
211 ACTIVITY, 14 7,, PROB (XX [3)), "TypeMFG2"; 
212 TypeRD2: 
ASSIGN, {{XX{S] ,0.1}, {XX{6] ,0.1}, {XX{7] ,o.s}, {XX{8] ,0.3}},1; 
213 ACTIVITY "ReRD"· 
214 TypeMFG2'.'~;SIGN, {{xx{9] ,0.2), {XX{l0] ,0.3}, {XX{ll] ,o.s}},1; 
215 ACTIVITY,,,, "ReMFG"; 
216 Split?: GOON,l; 
217 ACTIVITY,114, ,PROB(0.3), "ReIA"; 
218 ACTIVITY, 113,, PROB (0. 7), "RePMN"; 
219 Split6: GOON,l; 
220 ACTIVITY,106, ,PROB(0.1), "ReMFG 15"; 
221 ACTIVITY,107, ,PROB(0.l), "ReMFG=l7"; 
222 ACTIVITY,108, ,PROB{0.8}, "RePMN"; 
223 RD_27: COLCT,28,FIRSTARRIVE, " Identify Storage Criteria ",,, ,l; 
224 ACTIVITY,,,, "Accum2"; 
225 Re Packaging: GOON, 1; 
226 ACTIVITY,67,TRIAG(l,2,3); 
227 RD_ 28: COLCT,29,FIRSTARRIVE, "Identify Packaging Material",,, ,l; 
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228 ACTIVITY,68,TRIAG(l,2,3); 
229 RD 30 : COLCT,30,FIRSTARRIVE,"Evaluate Packaging Mat e ria l ",,,, l ; 
230 ACTIVITY,71, ,PROB(0.2), "RePackaging"; 
2 31 ACTIVITY, 70, , PROB ( 0 . 8) , "Accum2"; 
232 MFG 1: COLCT, 31, FIRSTARRIVE, "Construct Prel i minary GMP 
Manufact~ring Facility",,,, l; 
233 ACTIVITY,55,TRIAG(4,5,6); 
234 MFG_ 2 : COLCT,32,FIRSTARRIVE , "Identify and Qualify Al t e rn ate 
Vendors ",,,, l; 
235 ACTIVITY,77,TRIAG(3,4,5); 
236 MFG_3: COLCT,33,FIRSTARRIVE,"Install New Equipment",,,,l; 
237 ACTIVITY,,,, "Accum3"; 
238 ReRD_3 : GOON,1; 
239 ACTIVITY, 3, TRIAG ( 1, 3, 6); 
240 RD_3: COLCT,3,FIRSTARRIVE, "Research and Specify Raw Materia l s for 
Syringe",,,, 1; 
241 ACTIVITY,13,TRIAG(l,4,5); 
242 RD_13: COLCT, 13, FIRSTARRIVE, "Test for Suitability of Raw Materials 
for Syringe " ,,,, 1; 
243 ACTIVITY,43, ,PROB(O.l), "ReRD 3"; 
244 ACTIVITY,33, ,PROB(0.9), "Splitl"; 
245 ReRD _ 4: GOON,l; 
246 ACTIVITY, 4, TRIAG (3, 5, 6); 
247 RD_4: COLCT,4,FIRSTARRIVE, "Research and Specify Raw Materials for 
Pump Case",,,, 1; 
248 ACTIVITY, 14, TRIAG (2, 4, 5); 
249 RD_14: COLCT, 14, FIRSTARRIVE, "Test for Suitability of Raw Materials 
for Pump Case", , , , 1; 
2 50 ACTIVITY, 4 4, , PROB ( 0. 1) , "ReRD 4"; 
251 ACTIVITY,34, ,PROB(0.9), "Splitl"; 
252 ReRD _ 5: GOON,1; 
253 ACTIVITY,5,TRIAG(2,3,5); 
254 RD_5: COLCT,5,FIRSTARRIVE, "Research and Specify Raw Materials for 
Window Panel", , , , 1; 
255 ACTIVITY,15,TRIAG(3,4,8); 
256 RD_15: COLCT, 15, FIRSTARRIVE, "Test for Suitability of Raw Materials 
for Window Panel", , , , 1; 
257 ACTIVITY, 45,, PROB (0 .1), "ReRD_5"; 
258 ACTIVITY,35, ,PROB(0.9), "Splitl"; 
2 5 9 Re RD 6 : GOON, 1; 
260 ACTIVITY,6,TRIAG(4,6,8); 
261 RD_6: COLCT,6,FIRSTARRIVE, "Research and Specify Raw Mat eri al s f or 
Mechanical Driver Arrn",,, , 1; 
262 ACTIVITY, 16, TRIAG(l, 4, 8); 
2 63 RD_ 16: COLCT, 16, FIRSTARRIVE, "Test for Sui tabi li ty of Raw Mat er i als 
for Mechanical Driver Arm",,,, 1; 
264 ACTIVITY,46, ,PROB(0.1), "ReRD 6 "; 
265 ACTIVITY,36, ,PROB(0 . 9), "Splitl"; 
266 Re RD_ 7: GOON, 1; 
267 ACTIVITY,7,TRIAG(l,5,9); 
268 RD_7: COLCT, 7 , F I RSTARRIVE, "Research and Sp ec i f y Raw Ma t erials fo r 
Lead Screw",,, ,l; 
269 ACTI VI TY,17,TR I AG(3,5,6); 
270 RD_ 1 7 : COLCT, 17 ,FIRSTARRIVE,"Test for Su i tab ility of Ra w Materials 
for Lead Sc r ew", , , , 1; 
271 ACT I VI TY,47, ,PROB(O.l), "ReRD_7"; 
2 7 2 ACTIVITY,37, ,PROB(0.9), "Splitl"; 
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273 ReRD 8: GOON,1; 
274 ACTIVITY,8,TRIAG(2,6,7) ; 
275 RD 8: COLCT ,8, FIRSTARRIVE, " Research and Specify Raw Materials foi-
Re servoi r Converter ",,,, l ; 
276 ACT I VITY,18,TRIAG(2,5,8); 
277 RD_l8 : COLCT,18,FIRSTARRIVE, "Tes t for Suitability of Raw Mat erials 
for Reservoir Converter ",,,, l; 
278 ACTIVITY,48, ,PROB(O.l), "R eRD _ 8''; 
279 ACTIVITY,38, ,PR OB(0.9), "Splitl"; 
2 so ReRD 9 : GOON, 1 ; 
281 ACTIVITY, 9,TRIAG(l,4, 9}; 
282 RD_ 9 : COLCT , 9,FIRSTARRIVE, "Research and Specify Raw Mate ria l s for 
Luer Neck Lever'',,,,1; 
283 ACTIVITY, 19 , TRIAG {2, 3, 4) ; 
284 RD_1 9: COLCT, 19 , F IRSTARR IVE, "Test for Suitability of Raw Mater ials 
for Luer Neck Lever",,, , 1; 
285 ACTIVITY,49, ,PROB(O . l), "ReRD 9"; 
286 ACTIVITY,39, ,PROB(0.9), "Split l "; 
287 ReRD _ lO: GOON,1; 
288 ACTIVITY, 10 , TRIAG (2, 4, 5); 
289 RD_lO : COLCT, 10, FIRSTARRIVE, "Res earch and Specify Raw Mater ials 
for Battery Compartment",,,, 1 ; 
290 ACTIVITY, 20, TRIAG(3, 7, 8); 
291 RD_20: COLCT,20,F I RSTARRIVE, "Test for Suitability of Raw Material s 
for Battery Compartment",,,, 1; 
292 ACTIVITY,50, ,PROB(O.l), "R eRD 10"; 
293 ACTIVITY,40, ,PROB(0.9) , "Split l" ; 
294 ReRD 11: GOON,1; 
295 ACTIVITY, 11, TRIAG (7, 8, 9); 
296 RD 11: COLCT, 11, FIRSTARRIVE, "Develop Code for Software",,,, 1; 
297 ACTIVITY, 21, TRIAG (2, 3, 5) ; 
298 RD_21: COLCT,21,FIRSTARRIVE,"Test Software _Code",,,,l; 
299 ACTIVITY, 51,, PROB (0 . 1) , "ReRD 11"; 
300 ACTIVITY,41, ,PR OB(0 . 9) ,"Sp litl "; 
INSl - Pass 3 successfully read 
Translated network file BASECASE .TRN successfully written 
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AweSim Simulator, version 3 - 0 
Copyright (C) 1996 Pritsker Corporation 
Translated file BASECASE successfully read 
Translated file BASECASE TRN successfully read 
** AweSim Version 3. 0 ECHO REPORT ** 
Thu May 31 16 : 35 : 20 2001 
Simulation Project Insulin Pump Product and Process Development 
Modeler Dorene Seah 
Date 7/18/00 
Run options 
Run number 1 of 80 
Beginning time of run 0 . 000000 
Ending time of run 800. 000000 
Maximum errors during run 
Maximum entities in system 300 
Clear statistics between runs NO 
Execu t e simulation after input : YES 
Warn of destroyed entities YES 
Generate summary report EVERY (1) 
Variables 
Number of LL variables 
Number of XX variables 12 
Number of sz variables 
Number of entity ATRIBs; 
Number of entity LTRIBs : 
Number of entity STRIBs: 0 
Collect Information 
COLCT IDENTIFIER HISTOGRAM SPECIFICATIONS 
NUMBER NCEL HLOW HWID 
Determine Insuli 0. 0000 0. 0000 
Research and Spe . 0000 o. 0000 
Research and Spe . 0000 0 . 0000 
4 Research and Spe 0. 0000 0 . 0000 
5 Research and Spe .0000 o. 0000 
Research and Spe . 0000 0. 0000 
Research and Spe 0. 0000 0. 0000 
Research and Spe 0.0000 0. 0000 
Research and Spe 0.0000 0.0000 
10 Research and Spe 0. 0000 0 . 0000 
11 Develop Code for 0. 0000 0. 0000 
12 Test for Sui tabi 0 . 0000 0. 0000 
13 Test for Suitabi 0.0000 D .0000 
14 Test for Sui tabi o. 0000 D . 0000 
15 Test for Suitabi 0. 0000 0 . 0000 
16 Test for Sui tabi 0.0000 0. 0000 
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17 Test for Su tabi 0 .0000 0 0000 
18 Test for Su tabi 0 0 .0000 0.0000 
1 9 Test for Su tabi 0.0000 0 0000 
20 Test for Su tabi 0 0000 0.0000 
21 Test Software Co 0000 0.0000 
22 Determine Produc 0000 0. 0000 
23 Determine Steri l 0000 0. 0000 
24 Analyze Effects 0000 0000 
25 Analyze Particul 0.0000 . 0000 
26 Run Tests to Inv 0 0000 0.0000 
27 Perform Failure- 0.0000 0 0000 
28 Identify Storage 0.0000 0 0000 
29 Identify Packagi 0. 0000 0 0000 
30 Evaluate Packagi 0. 0000 0. 0000 
31 Construct Prelim .0000 0. 0000 
32 Identify and Qua . 0000 0 . 0000 
33 Install New Equi 0.0000 0.0000 
34 Establish Formal 0.0000 0 0000 
35 Determine Batch 0000 0 0000 
36 Discuss with Res 0000 . .0000 
37 Propose New Tech 0. 0000 . 0000 
38 Manufacture Insu 0. 0000 0 . 0000 
39 Assemble Solenoi 0 0. 0000 0. 0000 
40 Test Solenoid Mo 0 0 . 0000 0000 
41 Assemble Electro 0. 0000 0000 
42 Test Electronics 0. 0000 0. 0000 
43 Assemble Solenoi 0. 0000 0 0000 
44 Test Solenoid Mo . 0000 0 0000 
45 Assemble Final p 0 . 0000 0.0000 
46 Test Final Produ 0 0. 0000 . 0000 
47 Validate Insulin . 0000 . 0000 
48 Ensure Environme .0000 0. 0000 
49 File for Investi 0.0000 . 0000 
50 Submit Investiga 0.0000 .0000 
51 Perform Clinical 0000 0.0000 
52 Submit Premarket .0000 .0000 
53 Prepare Insulin 0. 0000 . 0000 
54 Insulin Pump Rea . 0000 0. 0000 
55 ReRawFrReRD . 0000 0. 0000 
56 ReProdFrReRD 0. 0000 0. 0000 
57 ReManufactureFrR 0. 0000 0. 0000 
Random Number Streams Information 
STREAM SEED REINITIALIZATION 
NUMBER VALUE OF STREAM 
1 428956419 NO 





7 200496737 NO 
8 633816299 NO 
1410143363 NO 
10 1282538739 NO 
11 794026294 NO 
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12 977821281 NO 
13 699858332 NO 
14 1683733431 NO 
15 96358723 NO 
16 602885281 NO 
17 871633513 NO 
18 1984612552 NO 
19 232391877 NO 
20 1356184 79 NO 
21 1814383333 NO 
22 324184021 NO 
23 1667630903 NO 
24 1082038467 NO 
25 18859997 11 NO 
26 111454913 NO 
27 1262746665 NO 
28 725514806 NO 
29 2087308334 NO 
30 1027457115 NO 
31 1716773784 NO 
32 1417840845 NO 
33 1401170757 NO 
34 505042365 NO 
35 1554339362 NO 
36 1747494519 NO 
37 93505551 NO 
38 194910479 NO 
39 1297383121 NO 
40 806401626 NO 
41 1242558033 NO 
42 1722906649 NO 
43 1195299681 NO 
44 57081438 NO 
45 817128895 NO 
46 1919094954 NO 
47 1435250780 NO 
48 1278785392 NO 
49 1309679730 NO 
so 1281484595 NO 
51 394601628 NO 
52 85886326 NO 
53 1571729619 NO 
54 918904909 NO 
55 1864761823 NO 
56 1268956513 NO 
57 1034484093 NO 
58 1763605842 NO 
59 1039242913 NO 
60 1322164949 NO 
61 1783293536 NO 
62 70884048 NO 
63 1420035359 NO 
64 994868838 NO 
65 1463578868 NO 
66 790460117 NO 
67 1431310689 NO 
68 268966977 NO 
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69 144 664 7089 NO 
70 1990098112 NO 
71 893770676 NO 
72 756136149 NO 
73 1758938931 NO 
74 1098677441 NO 
75 1178898083 NO 
76 27105414 7 NO 
77 1009598300 NO 
78 2114861268 NO 
79 1617952069 NO 
80 1131840250 NO 
81 2094070757 NO 
82 1 95319339 NO 
83 1659214966 NO 
8 4 1440396285 NO 
85 563832118 NO 
86 17025 1 0512 NO 
87 1721643437 NO 
88 2054527950 NO 
89 231008758 NO 
90 811760922 NO 
91 931 4 21337 NO 
92 2056682338 NO 
93 1224747865 NO 
94 2087343551 NO 
95 434301072 NO 
96 1002794063 NO 
97 1132277789 NO 
98 1505059305 NO 
99 208486230 NO 
100 1769772683 NO 
Intermediate results for run 1 
Maximum number of entities concurrently in system is 12 
Intermediate results for run 2 
Maxi mum number of entit i es concurrently in system is 10 
Intermediate results for run 3 
Maximum number of entities concurrently in system is 10 
I ntermediate results for run 4 
Maximum number of entities concurrently in system is 10 
Intermediate results for run S 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 6 
Maximum number of entities concurrently in system is 12 
Intermediate results for run 7 
Maximum number of entities concurrently in system is 10 
Intermediate results for run a 
Maximum number of entities concurrently in system is 10 
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Intermediate results for run 9 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 10 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 11 
Maximum number of entities concurrently in system is 10 
Interm e diate results for run 12 
Maximum number o f entities concurrently i n system is 10 
Intermediat e results for run 13 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 14 
Maximum num b er o f entities concur r ently in system is 10 
Intermediate results for run 15 
Ma x imum number of en t i t ies concurrent l y in system is 10 
Intermediate results for run 16 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 17 
Maxim um number of entities concurrently in system is 10 
Intermediate results for run 18 
Maximum number of ent i ties concurrently in system is 10 
Intermediate results for run 19 
Maxi mum number of entities concurrently in system is 12 
Intermediate results for run 20 
Ma ximum number of entities concurrently in system is 10 
Interm e diate results for run 21 
Maximum number o f entities concurrently in system is 92 
I n termediate results for run 22 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 23 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 24 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 25 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 26 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 27 
Maximum number of entities concurrently in system is 10 
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Intermediate results for run 28 
Max imum number of entities concurrently in system is 10 
Intermediat e results for run 29 
Maximum number of entities concurrently in system is 10 
Inter mediate results for run 30 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 31 
Maximum number of entities concurrently in system is 12 
Intermediate results for run 3 2 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 33 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 34 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 35 
Maximum number of entities concurrently in system is 46 
Intermediate results for run 36 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 37 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 38 
Maximum number of entities concurrently in system is 12 
Intermediate results for run 39 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 40 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 41 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 42 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 43 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 44 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 4 5 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 46 
Max imum number of entities concurrently in system is 10 
I 73 
Intermediate results for run 47 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 48 
Maximum number of entities concurrently in system is 34 
Intermediate results for run 49 
Maximum number of entities concurrently in system is 59 
Intermediate results for run 50 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 51 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 52 
Maximum number o f entities concurrently in system is 10 
Intermediate results for run 53 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 54 
Maximum number of entities concurrently in system is 10 
Intermediate resu l ts for run 55 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 56 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 57 
Max imum number of entities concurrently in system is 10 
Intermediate results for run 58 
Maximum number of entities concurrently in system is 12 
Intermediate results for run 59 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 60 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 61 
Max i mum number of entities concurrently in system is 10 
Intermediate resu l ts for run 62 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 63 
Maximum number of entities concurrently in system is 10 
Intermediate results for run 64 
Maximum number of entities concurrently in system is 12 
Intermediate results for run 65 
Maximum number of entities concurrently in system is 10 
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Inte rmed iate results for run 66 
Maximum numb er of entities co ncurren tly in system is 59 
Int ermediate resu lts for run 67 
Maximum number of entities concurre ntly in system i s 10 
I ntermediate r es u lts for run 68 
Maximum nu mber o f en titi es concurrently in system is 10 
Inte rmed i ate results for run 69 
Maximum number of entitie s concur r ently i n system is 10 
Intermediate results for run 70 
Maximum numbe r of entities concurre ntly in system is 10 
Intermediate results for run 71 
Maximum number of entities concurr ent l y in system is 10 
Intermediate results for run 72 
Maximum number of entities concurrently in . system is 96 
I ntermediate results for run 73 
Maximum number of entities concurr ently in system is 10 
Intermediate results for run 74 
Maximum number of entities co ncurrent l y in system is 10 
Intermediate results for run 75 
Maximum number of entities concurrently in system is 97 
Intermediate results for run 76 
Maximum number of entities concurrently in system is 10 
I ntermediate results for run 77 
Maximum number of enti ties concur rently in system is 10 
In termediate results for run 78 
Max imu m number of entities concurre nt ly in system is 54 
Intermediate results for run 79 
Maximum number of entities concur rently in system is 10 
Intermediate results f or run 80 
Maximum number of entities concurre nt ly in system is 10 
o total errors dur ing executi on 
I 75 
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a project plan. They include a 
s used, policies and procedures, 
e requirements, performance 
, and auditing. 
analysis of human resources, 
Critical Path Method (CPM), 
Gantt charts , as well as tracking 
ject scheduling, a network is 
g or ending point for a group of 
ceed from one event or point in 
own in Figure 2. The circles, 
anches, represent activities. In 
s. The number over the arrow 
ther event. Under each arrow is 
